dalteparin has been researched along with Pregnancy in 385 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Antepartum prophylactic dalteparin does not reduce the occurrence of venous thromboembolism, pregnancy loss, or placenta-mediated pregnancy complications in pregnant women with thrombophilia at high risk of these complications and is associated with an increased risk of minor bleeding." | 9.19 | Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. ( Chan, WS; Clement, AM; Coat, S; Demers, C; Dwyer, J; Greer, IA; Hague, WM; Hinshaw, K; Kahn, SR; Karovitch, A; Keely, E; Khandelwal, M; Khurana, R; Kingdom, J; Kovacs, MJ; Le Gal, G; McDonald, S; McLeod, A; Newstead-Angel, J; Rey, E; Robinson, S; Rodger, MA; Rosene-Montella, K; Said, J; Sermer, M; Silver, RM; Smith, G; Solymoss, S; Walker, M; Wells, PS, 2014) |
| "To assess whether treatment with enoxaparin and low-dose aspirin, along with intensive pregnancy surveillance, reduces rate of pregnancy loss compared with intensive pregnancy surveillance alone in women with history of 2 or more consecutive previous pregnancy losses, a parallel group, multicenter, randomized controlled trial was performed in the United Kingdom and New Zealand." | 9.14 | SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. ( Clark, P; Crichton, L; Greaves, M; Greer, IA; Langhorne, P; Thomson, A; Walker, ID; Whyte, S, 2010) |
| "Between August 1 2000 and June 20 2007, 116 pregnant women with: (i) | 9.14 | Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. ( David, M; Demers, C; Garneau, P; Gauthier, R; Kahn, SR; Leduc, L; Magee, LA; Michon, N; Morin, F; Rey, E; Rodger, M, 2009) |
| "We sought to determine whether long-term prophylactic dalteparin in pregnancy leads to loss of BMD." | 9.12 | Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. ( Clement, AM; Cranney, A; Hague, WM; Hodsman, A; Kahn, SR; Kovacs, MJ; Lazo-Langner, A; Rodger, MA, 2007) |
| "The purpose of this study was to determine whether standard therapeutic doses of dalteparin maintain peak therapeutic levels of anticoagulation during pregnancy." | 9.11 | A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. ( Barbour, LA; Oja, JL; Schultz, LK, 2004) |
| "To determine if a prophylactic dose of dalteparin, 5000 IU daily, and if the adjusted-weight dalteparin therapeutic dose of 100 IU/kg twice daily are appropriate in pregnancy." | 9.09 | Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. ( Rey, E; Rivard, GE, 2000) |
| "Seventeen women with previously verified thromboembolism were included in a pharmacokinetic evaluation of dalteparin during the third trimester of pregnancy." | 9.08 | A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ( Blombäck, M; Bremme, K; Hellgren, M; Lindberg, H, 1998) |
| "A systematic review of studies published between 1 January 1985 and 31 August 2017 was performed to analyse the efficacy of the low-molecular-weight heparin, dalteparin, in venous thromboembolism (VTE) treatment and prophylaxis during pregnancy, and to evaluate dosing practices, anticoagulant monitoring and adverse events." | 9.01 | Obstetric venous thromboembolism: a systematic review of dalteparin and pregnancy. ( Hellgren, M; Mistafa, O, 2019) |
| "To evaluate the efficacy and safety of anticoagulant agents, such as aspirin and heparin, in women with a history of at least two unexplained miscarriages with or without inherited thrombophilia." | 8.90 | Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. ( de Jong, PG; Di Nisio, M; Goddijn, M; Kaandorp, S; Middeldorp, S, 2014) |
| "The present study suggests that pravastatin may improve pregnancy outcomes in women with refractory obstetric APS when taken at the onset of PE or IUGR until the end of pregnancy." | 7.83 | Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. ( Dagklis, T; Girardi, G; Lefkou, E; Mamopoulos, A; Rousso, D; Vosnakis, C, 2016) |
| "Dalteparin is often used for prophylaxis or treatment of venous thromboembolism during pregnancy, yet there is no laboratory test to accurately reflect its clinical activity." | 7.83 | The effect of dalteparin on thromboelastography in pregnancy: an in vitro study. ( Archer, D; Carr, A; Chow, L; Lee, A; MacKenzie, L; Walker, A, 2016) |
| " Villous tissue was incubated at 2% O2 (hypoxia), 8% O2 and standard culture conditions (21% O2) or at 2% O2 and 21% O2 with dalteparin or ASA." | 7.80 | Hypoxia and the anticoagulants dalteparin and acetylsalicylic acid affect human placental amino acid transport. ( Darashchonak, N; Erlenwein, SV; Kleppa, MJ; von Kaisenberg, CS; von Versen-Höynck, F, 2014) |
| "Even though the use of acenocoumarol throughout pregnancy replaced by LMWH in the 1st trimester was proven safe and efficacious in this case report, large randomized controlled studies are still needed to make definitive recommendations about optimal antithrombotic therapy in pregnant patients with mechanical heart valves." | 7.75 | Acenocoumarol and pregnancy outcome in a patient with mitral valve prosthesis: a case report. ( Antsaklis, A; Daskalakis, G; Loutradis, D; Papoutsis, D; Stefanidis, K, 2009) |
| "Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications." | 7.75 | Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009) |
| "We compared the pregnancy success rates and safety parameters of fondaparinux versus enoxaparin, combined with immunotherapy, in patients with a history of miscarriage and/or infertility and coagulant defects." | 7.75 | A retrospective analysis of fondaparinux versus enoxaparin treatment in women with infertility or pregnancy loss. ( Reed, JL; Winger, EE, 2009) |
| "The aim of this retrospective, observational study was to determine the impact of low-dose enoxaparin (20 mg) in conjunction with low-dose aspirin on the pregnancy outcome of women with antiphospholipid syndrome and recurrent miscarriage." | 7.75 | Treatment of recurrent miscarriage and antiphospholipid syndrome with low-dose enoxaparin and aspirin. ( Li, TC; Makris, M; Metwally, M; Mo, D; Saravelos, S, 2009) |
| "We have determined the immediate effects of the main coronary reperfusion procedures on the plasma concentrations of myeloperoxidase (MPO), pregnancy-associated plasma protein A (PAPP-A), fibrin monomer (FM) and D-dimer (DD)." | 7.74 | The effect of primary percutaneous coronary intervention as compared to tenecteplase on myeloperoxidase, pregnancy-associated plasma protein A, soluble fibrin and D-dimer in acute myocardial infarction. ( Brügger-Andersen, T; Grundt, H; Hetland, Ø; Nilsen, DW; Pönitz, V, 2007) |
| "To evaluate the benefit of treatment with dalteparin and low-dose aspirin (ASA) in the prevention of obstetric complications in women with inherited thrombophilia." | 7.74 | Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007) |
| "Our study suggests that dalteparin may be used for the treatment of acute venous thromboembolism in pregnancy." | 7.72 | Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. ( Jacobsen, AF; Qvigstad, E; Sandset, PM, 2003) |
| "Under the therapy with LMWH (dalteparin-Na), no thromboembolic events during pregnancy or post partum could be observed." | 7.71 | [Prevention of thromboembolism with low molecular weight heparin (Dalteparin-Na) in risk pregnancy]. ( Bahlmann, F; Himmrich, L; Klotz, M; Peetz, D; Savvidis, S; Schinzel, H, 2002) |
| "Dalteparin sodium injection in patients with an immunologic component to RPL resulted in an increase in compliance without any adverse early pregnancy outcomes." | 7.70 | Dalteparin sodium injection treatment in patients with immunologic recurrent pregnancy loss. ( Trott, AM; Trott, EA, 2000) |
| " No adverse maternal-fetal side effects were reported on enoxaparin alone or enoxaparin-metformin." | 6.74 | Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss. ( Glueck, CJ; Goldenberg, N; Khan, N; Ramidi, G; Wang, P, 2009) |
| "Hypercoagulability is observed in patients with inherited thrombophilia, e." | 6.70 | The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation. ( Eberl, E; Geisen, U; Grossmann, R; Keller, F; Schambeck, CM, 2001) |
| "Dalteparin or dextran was used during delivery." | 6.69 | Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study. ( Blombäck, M; Bremme, K; Hellgren, M; Lindberg, H; Siegbahn, A, 1998) |
| "Dalteparin was not stopped in any women." | 5.91 | Prophylactic Dose of Dalteparin in Pregnant Women With History of Venous Thromboembolisms and/or Thrombophilia: Real-World Data. ( Kozak, M; Novak, A; Novak, P; Šabović, M, 2023) |
| "Human pregnancy is a hypercoagulable state with an increase in spontaneous platelet aggregation (SPA) in vivo." | 5.34 | Comparison of the effects of unfractionated heparin and the low-molecular-weight heparins dalteparin and enoxaparin on spontaneous platelet aggregation and adenosine diphosphate activity in platelets during the third trimester of pregnancy. ( Ajayi, AA; Cooper, J; Horn, EH; Pharmacols, FB; Rubin, PC, 2007) |
| "Screening results for thrombophilia and antithrombotic treatment with enoxaparin, aspirin, or both and pregnancy outcomes." | 5.27 | The Prevalence of Thrombophilia in Women With Recurrent Fetal Loss and Outcome of Anticoagulation Therapy for the Prevention of Miscarriages. ( Elias, A; Elias, M; Nahas, R; Saliba, W, 2018) |
| " The study group included 150 patients receiving LMWH (Tinzaparin sodium 4500 IU) subcutaneous daily injection with 500 µg folic acid once daily orally started once positive pregnancy test till the 20th week of gestation." | 5.24 | Low-Molecular-Weight Heparin for the Treatment of Unexplained Recurrent Miscarriage With Negative Antiphospholipid Antibodies: A Randomized Controlled Trial. ( Abbas, AM; Anan, MA; Fathalla, MM; Salman, SA; Shaaban, OM; Zahran, KM, 2017) |
| "Antepartum prophylactic dalteparin does not reduce the occurrence of venous thromboembolism, pregnancy loss, or placenta-mediated pregnancy complications in pregnant women with thrombophilia at high risk of these complications and is associated with an increased risk of minor bleeding." | 5.19 | Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. ( Chan, WS; Clement, AM; Coat, S; Demers, C; Dwyer, J; Greer, IA; Hague, WM; Hinshaw, K; Kahn, SR; Karovitch, A; Keely, E; Khandelwal, M; Khurana, R; Kingdom, J; Kovacs, MJ; Le Gal, G; McDonald, S; McLeod, A; Newstead-Angel, J; Rey, E; Robinson, S; Rodger, MA; Rosene-Montella, K; Said, J; Sermer, M; Silver, RM; Smith, G; Solymoss, S; Walker, M; Wells, PS, 2014) |
| "Through a non-randomized clinical trial, we examined the theoretical benefit of the coadministration of low molecular weight heparin (LMWH) and prednisolone on pregnancy outcomes in women with previously failed IVF/ICSI cycles." | 5.17 | Addition of prednisolone and heparin in patients with failed IVF/ICSI cycles: a preliminary report of a clinical trial. ( Chrelias, C; Creatsa, M; Iliodromiti, Z; Kassanos, D; Siristatidis, C; Varounis, C; Vrachnis, N, 2013) |
| "To determine whether low molecular weight heparin (LMWH) plus low-dose aspirin (LDA) is comparable in efficacy and safety to unfractionated heparin (UFH) plus LDA in the management of pregnant women with a history of recurrent spontaneous abortion secondary to antiphospholipid syndrome (APS)." | 5.15 | Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. ( Abdou, AM; Fouda, IM; Fouda, UM; Ramadan, DI; Sayed, AM; Zaki, MM, 2011) |
| " We then randomly assigned them to receive daily 80 mg of aspirin plus open-label subcutaneous nadroparin (at a dose of 2850 IU, starting as soon as a viable pregnancy was demonstrated), 80 mg of aspirin alone, or placebo." | 5.14 | Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. ( Büller, HR; Folkeringa, N; Goddijn, M; Hamulyák, K; Hutten, BA; Kaandorp, SP; Middeldorp, S; Mol, BW; Nahuis, M; Papatsonis, DN; van der Post, JA; van der Veen, F; Verhoeve, HR, 2010) |
| "To assess whether treatment with enoxaparin and low-dose aspirin, along with intensive pregnancy surveillance, reduces rate of pregnancy loss compared with intensive pregnancy surveillance alone in women with history of 2 or more consecutive previous pregnancy losses, a parallel group, multicenter, randomized controlled trial was performed in the United Kingdom and New Zealand." | 5.14 | SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage. ( Clark, P; Crichton, L; Greaves, M; Greer, IA; Langhorne, P; Thomson, A; Walker, ID; Whyte, S, 2010) |
| "Between August 1 2000 and June 20 2007, 116 pregnant women with: (i) | 5.14 | Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. ( David, M; Demers, C; Garneau, P; Gauthier, R; Kahn, SR; Leduc, L; Magee, LA; Michon, N; Morin, F; Rey, E; Rodger, M, 2009) |
| "To compare the use of enoxaparin alone with combination therapy of prednisone, aspirin and progesterone in the treatment of women with idiopathic recurrent miscarriage (IRM) in terms of live births and pregnancy outcome." | 5.13 | Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study. ( El-Refaiey, AA; El-Tatongy, M; Fawzy, M; Mosbah, A; Shokeir, T; Warda, O, 2008) |
| "To compare the effect of aspirin and enoxaparin on live births in women with unexplained recurrent miscarriages, as well as secondary outcomes including birth weight, uterine and umbilical blood flows, and congenital malformations." | 5.12 | A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. ( Brenner, B; Carp, H; Dolitzky, M; Inbal, A; Segal, Y; Weiss, A, 2006) |
| "We sought to determine whether long-term prophylactic dalteparin in pregnancy leads to loss of BMD." | 5.12 | Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. ( Clement, AM; Cranney, A; Hague, WM; Hodsman, A; Kahn, SR; Kovacs, MJ; Lazo-Langner, A; Rodger, MA, 2007) |
| "To compare low molecular weight heparin (LMWH), specifically dalteparin, to unfractionated heparin (UFH) for the treatment of antiphospholipid antibody syndrome (APS) in pregnancy." | 5.11 | Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. ( Ballem, PJ; Ensom, MH; Ensworth, S; Houlihan, E; Purkiss, S; Stephenson, MD; Tsang, P, 2004) |
| "The purpose of this study was to determine whether standard therapeutic doses of dalteparin maintain peak therapeutic levels of anticoagulation during pregnancy." | 5.11 | A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. ( Barbour, LA; Oja, JL; Schultz, LK, 2004) |
| " In a randomised open study, 44 pregnant women with confirmed previous or current thromboembolism were randomised to receive either low-molecular-weight heparin, dalteparin (N = 21) once daily subcutaneously or unfractionated sodium heparin (UF heparin, N = 23) twice daily subcutaneously for thromboprophylaxis during pregnancy and puerperium." | 5.10 | Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. ( Hiilesmaa, V; Kaaja, R; Leinonen, P; Markkola, A; Pettilä, V, 2002) |
| "To determine if a prophylactic dose of dalteparin, 5000 IU daily, and if the adjusted-weight dalteparin therapeutic dose of 100 IU/kg twice daily are appropriate in pregnancy." | 5.09 | Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. ( Rey, E; Rivard, GE, 2000) |
| "Seventeen women with previously verified thromboembolism were included in a pharmacokinetic evaluation of dalteparin during the third trimester of pregnancy." | 5.08 | A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. ( Blombäck, M; Bremme, K; Hellgren, M; Lindberg, H, 1998) |
| "Literature on the efficacy and safety of enoxaparin for thromboembolism and thromboprophylaxis remains scanty, and therefore efficacy was not assessed; in terms of safety, when including other indications for enoxaparin in pregnancy, we found that enoxaparin was associated with significantly lower complications than aspirin." | 5.05 | Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis. ( Jacobson, B; Leisegang, R; Naidoo, P; Paek, D; Rambiritch, V; Sayre, T; Shan, J, 2020) |
| "A systematic review of studies published between 1 January 1985 and 31 August 2017 was performed to analyse the efficacy of the low-molecular-weight heparin, dalteparin, in venous thromboembolism (VTE) treatment and prophylaxis during pregnancy, and to evaluate dosing practices, anticoagulant monitoring and adverse events." | 5.01 | Obstetric venous thromboembolism: a systematic review of dalteparin and pregnancy. ( Hellgren, M; Mistafa, O, 2019) |
| "To evaluate the efficacy and safety of anticoagulant agents, such as aspirin and heparin, in women with a history of at least two unexplained miscarriages with or without inherited thrombophilia." | 4.90 | Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. ( de Jong, PG; Di Nisio, M; Goddijn, M; Kaandorp, S; Middeldorp, S, 2014) |
| " Low dose aspirin should be given to every pregnant woman with antiphospholipid antibodies, with the addition of low molecular weight heparin in those with previous thrombosis, previous fetal death or failure of monotherapy with aspirin." | 4.85 | [The antiphospholipid syndrome in the 21st century]. ( Egurbide, MV; Martinez-Berriotxoa, A; Ruiz-Irastorza, G, 2009) |
| " My physician recommended I use dalteparin during this pregnancy although, during my previous pregnancy, I had received subcutaneous heparin injections three times daily." | 4.82 | Low-molecular-weight heparins during pregnancy. ( Koren, G; Many, A, 2005) |
| " In the outpatient treatment of venous thromboembolism, tinzaparin has demonstrated similar efficacy to dalteparin sodium (dalteparin) and warfarin." | 4.82 | Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease. ( Cheer, SM; Dunn, CJ; Foster, R, 2004) |
| "The present study suggests that pravastatin may improve pregnancy outcomes in women with refractory obstetric APS when taken at the onset of PE or IUGR until the end of pregnancy." | 3.83 | Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. ( Dagklis, T; Girardi, G; Lefkou, E; Mamopoulos, A; Rousso, D; Vosnakis, C, 2016) |
| " Villous tissue was incubated at 2% O2 (hypoxia), 8% O2 and standard culture conditions (21% O2) or at 2% O2 and 21% O2 with dalteparin or ASA." | 3.80 | Hypoxia and the anticoagulants dalteparin and acetylsalicylic acid affect human placental amino acid transport. ( Darashchonak, N; Erlenwein, SV; Kleppa, MJ; von Kaisenberg, CS; von Versen-Höynck, F, 2014) |
| "Even though the use of acenocoumarol throughout pregnancy replaced by LMWH in the 1st trimester was proven safe and efficacious in this case report, large randomized controlled studies are still needed to make definitive recommendations about optimal antithrombotic therapy in pregnant patients with mechanical heart valves." | 3.75 | Acenocoumarol and pregnancy outcome in a patient with mitral valve prosthesis: a case report. ( Antsaklis, A; Daskalakis, G; Loutradis, D; Papoutsis, D; Stefanidis, K, 2009) |
| "Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications." | 3.75 | Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009) |
| " Pregnancy and fetal outcomes included miscarriage, stillbirth, baby death and live birth, small-for-gestational-age infants, warfarin embryopathy and warfarin-related fetal loss." | 3.75 | Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin. ( McCowan, LM; McLintock, C; North, RA, 2009) |
| "We compared the pregnancy success rates and safety parameters of fondaparinux versus enoxaparin, combined with immunotherapy, in patients with a history of miscarriage and/or infertility and coagulant defects." | 3.75 | A retrospective analysis of fondaparinux versus enoxaparin treatment in women with infertility or pregnancy loss. ( Reed, JL; Winger, EE, 2009) |
| "The aim of this retrospective, observational study was to determine the impact of low-dose enoxaparin (20 mg) in conjunction with low-dose aspirin on the pregnancy outcome of women with antiphospholipid syndrome and recurrent miscarriage." | 3.75 | Treatment of recurrent miscarriage and antiphospholipid syndrome with low-dose enoxaparin and aspirin. ( Li, TC; Makris, M; Metwally, M; Mo, D; Saravelos, S, 2009) |
| "We have determined the immediate effects of the main coronary reperfusion procedures on the plasma concentrations of myeloperoxidase (MPO), pregnancy-associated plasma protein A (PAPP-A), fibrin monomer (FM) and D-dimer (DD)." | 3.74 | The effect of primary percutaneous coronary intervention as compared to tenecteplase on myeloperoxidase, pregnancy-associated plasma protein A, soluble fibrin and D-dimer in acute myocardial infarction. ( Brügger-Andersen, T; Grundt, H; Hetland, Ø; Nilsen, DW; Pönitz, V, 2007) |
| "To evaluate the benefit of treatment with dalteparin and low-dose aspirin (ASA) in the prevention of obstetric complications in women with inherited thrombophilia." | 3.74 | Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007) |
| "Our study suggests that dalteparin may be used for the treatment of acute venous thromboembolism in pregnancy." | 3.72 | Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. ( Jacobsen, AF; Qvigstad, E; Sandset, PM, 2003) |
| "Heparin prophylaxis at fixed low doses and possibly aspirin could be efficacious in preventing adverse outcomes in women carrying inherited thrombophilia with previous poor obstetric outcomes." | 3.71 | Preventing adverse obstetric outcomes in women with genetic thrombophilia. ( Brancaccio, V; Colaizzo, D; Di Minno, G; Grandone, E; Margaglione, M; Pavone, G; Sciannamé, N, 2002) |
| "This prospective audit reports pregnancy outcomes, anticoagulation complications, and anti-Xa levels in women with mechanical heart valves who were treated with therapeutic enoxaparin plus aspirin during pregnancy." | 3.71 | Enoxaparin treatment in women with mechanical heart valves during pregnancy. ( McCowan, LM; North, RA; Raudkivi, PJ; Rowan, JA, 2001) |
| "Under the therapy with LMWH (dalteparin-Na), no thromboembolic events during pregnancy or post partum could be observed." | 3.71 | [Prevention of thromboembolism with low molecular weight heparin (Dalteparin-Na) in risk pregnancy]. ( Bahlmann, F; Himmrich, L; Klotz, M; Peetz, D; Savvidis, S; Schinzel, H, 2002) |
| " Aspirin, 75 mg daily was given in addition to enoxaparin to women with antiphospholipid syndrome." | 3.70 | Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. ( Blumenfeld, Z; Brenner, B; Hoffman, R; Weiner, Z; Younis, JS, 2000) |
| "Dalteparin sodium injection in patients with an immunologic component to RPL resulted in an increase in compliance without any adverse early pregnancy outcomes." | 3.70 | Dalteparin sodium injection treatment in patients with immunologic recurrent pregnancy loss. ( Trott, AM; Trott, EA, 2000) |
| "To evaluate fixed compared with weight-based enoxaparin dosing to achieve prophylactic anti-Xa levels after cesarean delivery." | 3.11 | Weight-Based Compared With Fixed-Dose Enoxaparin Prophylaxis After Cesarean Delivery: A Randomized Controlled Trial. ( Allshouse, AA; Branch, DW; Bruno, AM; Campbell, HM; Lim, MY; Metz, TD; Silver, RM, 2022) |
| "125 women with intrauterine growth restriction were randomized to control group and intervention group (receiving routine high risk pregnancy prenatal care plus daily subcutaneous injection of 40 mg enoxaparin)." | 3.01 | Therapeutic role of enoxaparin in intra-uterine growth restriction: A randomized clinical trial. ( Fathi, M; Golshahi, F; Naeiji, Z; Nazari, F; Sahebdel, B; Sharbaf, FR; Shirazi, M, 2021) |
| "Preeclampsia (PE) and intrauterine growth restriction (IUGR) are major causes of maternal and perinatal morbidity and mortality." | 2.94 | Early Prophylactic Enoxaparin for the Prevention of Preeclampsia and Intrauterine Growth Restriction: A Randomized Trial. ( Alijotas-Reig, J; Bella, M; Burgos, J; Cabero, L; Carreras, E; De Diego, R; Gómez-Roig, MD; Llurba, E; Martínez-Astorquiza, T; Mazarico, E; Sánchez, O; Sánchez-Durán, MÁ, 2020) |
| "The incidence of intrauterine growth restriction (IUGR) is estimated at about 3% of pregnancies, and it is associated with 30% of all perinatal mortality and severe morbidity with adverse neurodevelopmental and cardiovascular health consequences in adult life." | 2.87 | Study protocol for a randomised controlled trial: treatment of early intrauterine growth restriction with low molecular weight heparin (TRACIP). ( Camprubí, M; Figueras, F; Gomez Roig, MD; Ibáñez-Burillo, P; Masoller, N; Mazarico, E; Oros, D; Peguero, A; Rovira, C; Schoorlemmer, J; Tàssies, MD, 2018) |
| "To compare two enoxaparin dosing strategies at achieving prophylactic anti-Xa levels in women with a body mass index (BMI) ⩾35 (kg m(-2)) postcesarean delivery." | 2.82 | A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women. ( Caballero, DC; McNulty, J; Neeper, JM; Serra, AE; Stephenson, ML, 2016) |
| "Aspirin and heparin have been shown to have potentially beneficial effects on trophoblast implantation." | 2.79 | Low dose aspirin and low-molecular-weight heparin in the treatment of pregnant Libyan women with recurrent miscarriage. ( Adam, I; Ashur, BM; Elbareg, AM; Elmahashi, MO; Essadi, FM, 2014) |
| " While dosing of LMWH based on weight alone is standard for most non-pregnant patients, there is no data on the utility of this approach in pregnancy." | 2.78 | Weight-adjusted dosing of tinzaparin in pregnancy. ( Gibson, PS; Jiang, X; Mansoor, A; Newell, K; Ross, S; Sam, DX; Tang, S, 2013) |
| "2 U/mL, is safe for women with mechanical prosthetic heart valves (MPHV)." | 2.76 | A prospective trial showing the safety of adjusted-dose enoxaparin for thromboprophylaxis of pregnant women with mechanical prosthetic heart valves. ( Aziz, RH; Dominique, TG; Jacobson, BF; Pravin, M; Saeed, CR; Serasheini, M, 2011) |
| "Thrombophilia has been identified in about 50% of women with recurrent miscarriage and thromboprophylaxis has been suggested as an option of treatment." | 2.76 | Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. ( Bloemenkamp, KW; Helmerhorst, FM; Kaaja, RJ; Lampinen, K; Morin-Papunen, L; Ulander, VM; Visser, J, 2011) |
| " No adverse maternal-fetal side effects were reported on enoxaparin alone or enoxaparin-metformin." | 2.74 | Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss. ( Glueck, CJ; Goldenberg, N; Khan, N; Ramidi, G; Wang, P, 2009) |
| "In women with a history of recurrent miscarriage, the risk of miscarriage in a subsequent pregnancy is about 30% to 40%." | 2.74 | Use of heparin in women with early and late miscarriages with and without thrombophilia. ( Baumgarten, S; Dörner, T; Kadecki, O; Kiesewetter, H; Monien, S; Salama, A, 2009) |
| " Using enoxaparin pharmacokinetic parameters to simulate anti-Xa time profiles, we observed that the maintenance of the same doses throughout pregnancy resulted in a progressive reduction in mean and peak anti-Xa activities." | 2.73 | Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy. ( Amoura, Z; Ankri, A; Conard, J; Cornet, A; Costedoat-Chalumeau, N; Dommergues, M; Hulot, JS; Lebaudy, C; Lechat, P; Piette, JC; Serreau, R, 2008) |
| "In treated women, the relative risk for preeclampsia was 0." | 2.71 | Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. ( Abbate, R; Fatini, C; Gensini, F; Gensini, GF; Marchionni, M; Mello, G; Parretti, E; Riviello, C; Scarselli, GF, 2005) |
| "Hypercoagulability is observed in patients with inherited thrombophilia, e." | 2.70 | The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation. ( Eberl, E; Geisen, U; Grossmann, R; Keller, F; Schambeck, CM, 2001) |
| " This finding has significant implications for appropriate dosing of enoxaparin in pregnancy." | 2.69 | Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. ( Casele, HL; Laifer, SA; Venkataramanan, R; Woelkers, DA, 1999) |
| "Dalteparin or dextran was used during delivery." | 2.69 | Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study. ( Blombäck, M; Bremme, K; Hellgren, M; Lindberg, H; Siegbahn, A, 1998) |
| " We used American College of Obstetrics and Gynecology recommendations as the base for screening and dosing guidelines and utilized known and published absolute risk values and odds ratios to stratify risk factors." | 2.61 | Risk Assessment and Treatment Guide for Obstetric Thromboprophylaxis: Comprehensive Review of Current Guidelines. ( Deering, SH; Eubanks, AA; Thiel, LM, 2019) |
| "Compared with control intervention for recurrent miscarriage, enoxaparin treatment has no substantial influence on live births (RR = 1." | 2.61 | Enoxaparin (or plus aspirin) for the prevention of recurrent miscarriage: A meta-analysis of randomized controlled studies. ( Chen, Y; Cheng, X; Li, N; Lin, T; Sheng, X, 2019) |
| "Idiopathic pulmonary arterial hypertension is a rare and progressive condition which is aggravated by the physiologic changes during pregnancy." | 2.58 | Pregnancy outcome in a pregnant patient with idiopathic Pulmonary Arterial Hypertension: a case report and review of the literature. ( Rashidi, F; Sate, H, 2018) |
| "The authors report a pregnancy with fetal growth restriction at 36 weeks in a 31-year-old primigravida with symptomatic BD, treated with uninterrupted monthly IFX and daily enoxaparin." | 2.50 | Pregnancy management in Behçet's disease treated with uninterrupted infliximab. Report of a case with fetal growth restriction and mini-review of the literature. ( Correa, R; De Franciscis, P; Della Gala, A; Di Donna, MC; Ercolano, S; Esposito, E; Mainini, G; Stradella, L, 2014) |
| " Selection of the appropriate dosage is strongly recommended." | 2.45 | Safety evaluation of enoxaparin in currently approved indications. ( Meneveau, N, 2009) |
| "Enoxaparin is a low-molecular-weight heparin (LMWH) that differs substantially from unfractionated heparin (UFH) in its pharmacodynamic and pharmacokinetic properties." | 2.42 | Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice. ( Fareed, J; Hoppensteadt, D; Iqbal, O; Jeske, W; Ma, Q; Sheikh, T; Walenga, J, 2003) |
| "Women with thrombophilia have an increased risk of pregnancy loss and possibly other serious obstetric complications, although definition of the magnitude of risk will require prospective longitudinal studies." | 2.42 | Thrombophilia and pregnancy complications. ( Kujovich, JL, 2004) |
| " As prophylaxis, reviparin 1,750 anti-XaIU once daily was as effective as unfractionated heparin 5,000IU twice daily in 1,311 patients undergoing abdominal surgery and, in a once daily dosage of 4,200 anti-XaIU, was as effective as subcutaneous enoxaparin sodium 40 mg/day or acenocoumarol in patients undergoing hip replacement surgery." | 2.41 | Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism. ( Jarvis, B; McClellan, K; Wellington, K, 2001) |
| "Dalteparin is a low molecular weight heparin (LMWH) with a mean molecular weight of 5000." | 2.41 | Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease. ( Dunn, CJ; Jarvis, B, 2000) |
| "The third pregnancy was established and sintrom was stopped and replaced by fraxiparine 0." | 2.40 | [Successful prophylaxis in a pregnancy with thrombophilic states]. ( Bogdanova, M; Iankova, Z, 1999) |
| " The enhanced bioavailability of these drugs, in conjunction with their prolonged half-life, makes subcutaneous therapy, in one to two daily doses, possible." | 2.39 | Low molecular weight heparins and their use in obstetrics and gynecology. ( Fejgin, MD; Lourwood, DL, 1994) |
| "Dalteparin was not stopped in any women." | 1.91 | Prophylactic Dose of Dalteparin in Pregnant Women With History of Venous Thromboembolisms and/or Thrombophilia: Real-World Data. ( Kozak, M; Novak, A; Novak, P; Šabović, M, 2023) |
| " Hence, this real-world study aimed to explore the efficacy and safety of TNFi combined with intravenous immunoglobin (IVIG) and heparin therapy in RSA patients." | 1.72 | Tumour necrosis factor inhibitor combined with intravenous immunoglobulin and heparin for treatment of recurrent spontaneous abortion: A two-centre, retrospective, cohort study. ( Chen, J; Chen, X; Jiang, Y; Wu, H; You, Q; Zhang, N; Zou, Q, 2022) |
| "The evaluation criteria for dosage of low-molecular-weight heparin (LMWH) for pregnant women at high risk of venous thromboembolism (VTE) remain unclear." | 1.72 | Comparison of doses of heparin for venous thromboembolism and bleeding in pregnant women. ( Guo, L; Luo, Y; Mu, L; Xiao, S; Ye, Z; Zhang, J, 2022) |
| "Human pregnancy is associated with a mild proinflammatory state characterized by circulatory neutrophil activation which is further increased in complicated pregnancies, placenta-mediated complications being associated with an increased thrombotic risk." | 1.62 | NETosis Markers in Pregnancy: Effects Differ According to Histone Subtypes. ( Bouvier, S; Demattei, C; Fortier, M; Gris, JC; Herzog, M; Letouzey, V; Mercier, E; Mousty, E; Nouvellon, E; Rommelaere, G; Vincent, L, 2021) |
| "Acute pulmonary embolism and coronavirus disease were diagnosed." | 1.56 | COVID-19 and Acute Pulmonary Embolism in Postpartum Patient. ( Boogar, SS; Khodamoradi, Z; Kouhi, P; Shirazi, FKH, 2020) |
| "Preeclampsia is a serious hypertensive disorder of pregnancy, which is only cured with delivery of the placenta, thereby commonly necessitating preterm birth of the fetus." | 1.56 | The antithrombin binding regions of heparin mediate fetal growth and reduced placental damage in the RUPP model of preeclampsia†. ( Baczyk, D; Kingdom, JC; Wat, JM, 2020) |
| "High rates of postpartum hemorrhage are reported in our cohort." | 1.51 | Effectiveness and safety of thromboprophylaxis with enoxaparin for prevention of pregnancy-associated venous thromboembolism. ( Cox, S; Eslick, R; McLintock, C, 2019) |
| "National guidelines have been developed to ensure correct dosing of tinzaparin for women delivered by caesarean delivery (CD) to reduce the risk of venous thromboembolism." | 1.48 | Tinzaparin thromboprophylaxis prescribing practice after caesarean delivery 2009-2014. ( Maguire, PJ; McGuire, M; McNicholl, M; Power, KA; Sheehan, SR; Turner, MJ, 2018) |
| "One patient had deep venous thrombosis in the 6 weeks postpartum, in the GROUP P." | 1.46 | Is a therapeutic anticoagulation window needed for delivery when using prophylactic low molecular weight heparin during pregnancy? A retrospective monocentric study. ( Agman, A; Amsellem, J; Cesario, E; Nizard, J; Roueli, A; Vauthier-Brouzes, D, 2017) |
| " Multivariate logistic regression models were used to examine associations between first- and third-trimester exposure to enoxaparin, major malformations, and other adverse birth outcomes, adjusted for confounders." | 1.46 | The Fetal Safety of Enoxaparin Use During Pregnancy: A Population-Based Retrospective Cohort Study. ( Daniel, S; Fishman, B; Gorodischer, R; Koren, G; Levy, A; Matok, I; Shlomo, M; Wiznitzer, A, 2017) |
| "Thrombophilia was present in 38 (33." | 1.46 | Outcomes of threatened abortions after anticoagulation treatment to prevent recurrent pregnancy loss. ( Amsalem, H; Kalish, Y; Kleinstern, G; Rottenstreich, A, 2017) |
| " There is limited evidence to support current dosing and monitoring strategies of enoxaparin in this population." | 1.43 | Evaluation of therapeutic enoxaparin in a pregnant population at a tertiary hospital. ( Allen, J; Barras, M; Fagermo, N; Lust, K; Martin, JH; Petrie, S, 2016) |
| "These findings suggest that vertebral compression fractures and PPO may be one of the causes of severe back pain in postpartum patients." | 1.42 | Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy. ( Cakir, B; Dirikoc, A; Ersoy, R; Ozdemir, D; Tam, AA, 2015) |
| "To compare the adequacy of venous thromboembolism prophylaxis based on anti-Xa concentrations between weight-based enoxaparin dosing and body mass index (BMI)-stratified dosing in morbidly obese women after cesarean delivery." | 1.42 | Enoxaparin dosing after cesarean delivery in morbidly obese women. ( LaCoursiere, DY; Overcash, RT; Somers, AT, 2015) |
| " We investigated two different dosing regimens; fixed dose and weight-adjusted dose on the anticoagulant effects of the LMWH tinzaparin used for thromboprophylaxis in obese pregnant women." | 1.40 | Weight-adjusted LMWH prophylaxis provides more effective thrombin inhibition in morbidly obese pregnant women. ( Higgins, JR; Ismail, SK; Norris, L; O'Shea, S, 2014) |
| "Untreated hereditary antithrombin deficiency in pregnancy is associated with maternal venous thromboembolism (VTE) and possibly with fetal loss." | 1.39 | How I treat heterozygous hereditary antithrombin deficiency in pregnancy. ( Bramham, K; Hunt, BJ; Mitchell, M; Moore, GW; Retter, A; Robinson, SE, 2013) |
| " The physiological changes associated with pregnancy alter the pharmacokinetic profile of low-molecular-weight heparins, which has led to controversy and subsequent variation in practice, when pregnant women with venous thromboembolism are treated with low-molecular-weight heparins." | 1.39 | Population pharmacokinetics of enoxaparin during the antenatal period. ( Arya, R; Davies, JG; Green, B; Marsh, MS; Patel, JP; Patel, RK, 2013) |
| " Enoxaparin was administered after caesarean section using the Royal College of Obstetricians and Gynaecologists weight-adjusted dosing guidelines." | 1.39 | Peak plasma anti-Xa levels after first and third doses of enoxaparin in women receiving weight-based thromboprophylaxis following caesarean section: a prospective cohort study. ( Casey, E; Hiscock, RJ; Newell, PA; Simmons, SW; Walker, SP, 2013) |
| "Physiological changes during pregnancy can effect pharmacokinetic (PK) parameters, which may lead to altered dose requirements." | 1.38 | Leveraging physiological data from literature into a pharmacokinetic model to support informative clinical study design in pregnant women. ( Green, B; Morrish, GA; van Hasselt, JG, 2012) |
| "Among patients with cancer-related VTE, 59." | 1.38 | Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study. ( Blostein, M; Faucher, JP; Gamble, G; Game, M; Gordon, W; Kagoma, PK; Kahn, SR; Komari, N; Laverdière, D; Martineau, J; McLeod, A; Mills, A; Miron, MJ; Schulman, S; Springmann, V; Stewart, JA; Strulovitch, C, 2012) |
| "No reductions were observed in the thrombus size or mean mitral gradient on transesophageal echocardiography (TEE) with 1 week of unfractioned heparin therapy." | 1.37 | Partial thrombus resolution with trofiban in a pregnant woman with mechanical prosthetic mitral valve thrombosis. ( Akcay, AB; Akcay, M; Davutoglu, V; Sen, N; Soydinc, HE; Yuce, M, 2011) |
| "The incidence of severe pregnancy complications in previous pregnancies was similar in both groups." | 1.37 | Low molecular weight heparin treatment during subsequent pregnancies of women with inherited thrombophilia and previous severe pregnancy complications. ( Gamzu, R; Kupferminc, MJ; Lessing, JB; Many, A; Rimon, E; Sharon, M, 2011) |
| "To evaluate dosing requirements and monitoring patterns of low-molecular-weight heparin (LMWH) when used in high-risk pregnancy." | 1.37 | Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: single-center experience. ( Chevalier, AB; Hibbard, JU; Kominiarek, MA; Nutescu, EA; Shapiro, NL, 2011) |
| " For those records documenting tinzaparin use and pregnancy outcome, information was extracted into a standardised case report form; these were reviewed for adverse events, which were submitted for adjudication by independent experts in obstetric medicine and haematology." | 1.37 | Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile. ( Borg, JY; Greer, IA; Nelson-Piercy, C; Powrie, R; Rodger, M; Stinson, J; Talbot, DJ, 2011) |
| "Nadroparin is both safe and effective for the treatment of DVT during pregnancy and puerperium." | 1.36 | Efficacy and safety of nadroparin and unfractionated heparin for the treatment of venous thromboembolism during pregnancy and puerperium. ( Antonijević, N; Djordjević, V; Ilić, V; Kovac, M; Lazić, R; Mitić, G; Novakov-Mikić, A; Povazan, L; Salatić, I, 2010) |
| "Given that deep vein thrombosis coincided with obstetric delivery, it was crucial to decide on anesthetic and therapeutic approaches that would assure maternal and fetal safety and prevent such complications as massive pulmonary thromboembolism." | 1.36 | [Parturient at full term with inferior vena cava thrombosis: anesthesia during surgical delivery]. ( Amorós, B; Bermejo, L; Dueñas, N; Fernández, E; Perea, M; Villafranca, A, 2010) |
| "The pregnancy was carried to term and she delivered a healthy boy at 38 weeks of gestation." | 1.36 | Successful surgical management of massive pulmonary embolism during the second trimester in a parturient with heparin-induced thrombocytopenia. ( Corbi, P; Hajj-Chahine, J; Jayle, C; Tomasi, J, 2010) |
| "Gastrointestinal stromal tumors are the commonest stromal tumors of the digestive tract." | 1.36 | [Gastrointestinal stromal tumor in pregnancy and control. Case report]. ( Cuerva-González, MJ; de la Calle-Fernández, M; Lacoponi, S; Pozo-Krielinger, J, 2010) |
| "The dalteparin-treated group showed a significantly (30%) shorter labor time compared to matched controls." | 1.36 | Does low molecular weight heparin shorten term labor? ( Akerud, A; Dubicke, A; Ekman-Ordeberg, G; Hellgren, M; Malmström, A, 2010) |
| "To evaluate the safety of individually dosed low molecular weight heparin (LMWH) for prophylaxis and treatment of thromboembolic complications in pregnancy." | 1.36 | Venous thromboembolism in pregnancy: prophylaxis and treatment with low molecular weight heparin. ( Andersen, AS; Bergholt, T; Berthelsen, JG, 2010) |
| ": An intracranial subdural hematoma is a rare and potentially fatal complication of spinal anesthesia." | 1.35 | Intracranial subdural hematoma after spinal anesthesia in a parturient. ( Dawley, B; Hendrix, A, 2009) |
| "Intravenous magnesium sulfate for seizure prophylaxis and oxytocin for induction of labor were started." | 1.35 | Systemic lupus erythematosus presenting with leukocytoclastic vasculitis and seizure during pregnancy. ( Borahay, MA; Harirah, HM; Kelly, BC, 2009) |
| "Severe postpartum hemorrhage is an infrequent complication when enoxaparin is administered to hemostatically intact women between 5 and 24 h following a vaginal delivery or 12-36 h following cesarean section." | 1.35 | Timing of postpartum enoxaparin administration and severe postpartum hemorrhage. ( Bauer, KA; Freedman, RA; Neuberg, DS; Zwicker, JI, 2008) |
| "The recommended dosage of tinzaparin in the treatment of thromboembolism during pregnancy is 175 IU/kg/day, as for non-pregnant subjects." | 1.35 | Treatment of deep venous thrombosis in pregnant women. ( Grønlykke, T; Langhoff-Roos, J; Lykke, JA, 2008) |
| "Human pregnancy is a hypercoagulable state with an increase in spontaneous platelet aggregation (SPA) in vivo." | 1.34 | Comparison of the effects of unfractionated heparin and the low-molecular-weight heparins dalteparin and enoxaparin on spontaneous platelet aggregation and adenosine diphosphate activity in platelets during the third trimester of pregnancy. ( Ajayi, AA; Cooper, J; Horn, EH; Pharmacols, FB; Rubin, PC, 2007) |
| " The results of this study indicate that nadroparin alone is useful and safe in the management of pregnant patients with APS." | 1.33 | Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study. ( Chiarelli, S; De Silvestro, G; Fais, G; Favaro, M; Pengo, V; Ruffatti, A; Suma, V; Todesco, S; Tonello, M, 2005) |
| "Discontinuing LMWH more than 12 hours before delivery is safe in relation to maternal hemorrhagic complications." | 1.33 | The safety of low molecular weight heparin therapy during labor. ( Kupferminc, MJ; Landsberg, JA; Lessing, JB; Many, A; Maslovitz, S; Varon, D, 2005) |
| " Anti-Xa levels may reflect inadequate dosing of low molecular weight heparin, particularly during the first trimester, and should be monitored frequently." | 1.33 | Budd-Chiari syndrome, systemic lupus erythematosus, and secondary antiphospholipid antibody syndrome in pregnancy. ( Aisenbrey, GA; Argubright, KF; Joffe, GM, 2005) |
| "Inherited thrombophilia is associated with thromboembolic events and/or poor obstetric outcome." | 1.33 | Inherited thrombophilia: treatment during pregnancy. ( Caruso, A; De Carolis, S; De Stefano, V; Fatigante, G; Ferrazzani, S; Garofalo, S; Leone, G; Rossi, E, 2006) |
| "Subchorionic hematoma is a potentially serious complication that can occur in pregnant patients receiving enoxaparin for the prevention of thromboembolism." | 1.33 | Massive subchorionic hematoma associated with enoxaparin. ( Goodwin, TM; Lee, RH, 2006) |
| " Dosing was determined individually by the investigators with a goal of maintaining an AT activity of 80 to 150 percent." | 1.32 | Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. ( Bauer, KA; Bonfiglio, J; Greist, A; Holmes, HE; Konkle, BA; Weinstein, R, 2003) |
| " The lowest dose-response curve was at 36 weeks' gestation." | 1.32 | A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. ( Back, DJ; Cowan, C; Farquharson, RG; Quenby, SM; Sephton, V; Toh, CH; Topping, J, 2003) |
| "Lovenox (enoxaparin sodium) therapy appears to be safe and efficacious for pregnant women who are candidates for either prophylactic or therapeutic heparin." | 1.31 | ACOG Committee Opinion: safety of Lovenox in pregnancy. ( , 2002) |
| "Lovenox (enoxaparin sodium) therapy appears to be safe and efficacious for pregnant women who are candidates for either prophylactic or therapeutic heparin." | 1.31 | ACOG committee opinion. Safety of Lovenox in pregnancy. Number 276, October 2002. Committee on Obstetric Practice. ( , 2002) |
| "Incidence, seriousness and causality of maternal, fetal and neonatal adverse events, pregnancy outcome, and incidence of venous thromboembolism." | 1.31 | Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. ( Borel-Derlon, A; Borg, JY; Boudignat, O; Cohen, C; Conard, J; Darmon, JY; Francoual, C; Lepercq, J; Priollet, P; Schved, JF; Tournaire, M; Yvelin, N, 2001) |
| " The objectives of this investigation were to characterize the safety and pharmacokinetic behavior of a low-molecular weight heparin (reviparin) administered throughout pregnancy." | 1.31 | Pharmacokinetic profile of a low-molecular weight heparin (reviparin) in pregnant patients. A prospective cohort study. ( Crowther, MA; Crowther, R; Ginsberg, J; Johnston, M; Julian, J; Laskin, C; Spitzer, K, 2000) |
| "We report a pregnant woman with systemic lupus erythematosus and recurrent venous thromboembolism who suffered from heparin-induced thrombocytopenia type II while treated with dalteparin sodium." | 1.31 | Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin. ( Geberth, M; Harenberg, J; Heene, DL; Hoffmann, U; Huhle, G, 2000) |
| " One daily dosage of 5,000 IU anti-Xa resulted in a measurable level of FXa for 24 h in pregnancy week 40, compared with 17h at pregnancy week 37." | 1.31 | Accumulation of low molecular mass heparin during prophylactic treatment in pregnancy. ( Blombäck, M; Bremme, K; van Rooijen, M; Yu, A, 2001) |
| "We studied the outcome of 41 pregnancies in an attempt to identify an appropriate and safe anticoagulant regimen for pregnant women with cardiac valve prosthesis." | 1.30 | Is there a safe anticoagulation protocol for pregnant women with prosthetic valves? ( Alam, SE; Arnaout, MS; Karam, K; Kazma, H; Khalil, A; Nasrallah, A; Shasha, N, 1998) |
| " The mean time for dosage increase was 20." | 1.30 | Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. ( Buchanan, N; Copplestone, A; Doughty, HA; Hughes, G; Hunt, BJ; Kerslake, S; Khamashta, M; Majumdar, G, 1997) |
| "We present a case of pulmonary embolism successfully treated with low molecular weight heparin in a woman with a major grade placenta praevia, who required emergency operative delivery." | 1.30 | Thromboembolism treated with low molecular weight heparin in a pregnancy complicated by major placenta praevia: a case report. ( Hertzberg, M; Lahoud, R; Nicholl, M; Rowlands, S, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 33 (8.57) | 18.2507 |
| 2000's | 169 (43.90) | 29.6817 |
| 2010's | 154 (40.00) | 24.3611 |
| 2020's | 29 (7.53) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, W | 1 |
| Zhang, X | 2 |
| Sun, S | 1 |
| Wang, Q | 1 |
| Li, C | 1 |
| Zhao, A | 1 |
| Chen, T | 1 |
| Lan, L | 1 |
| Sun, W | 1 |
| Yu, J | 1 |
| Lu, B | 1 |
| Chen, L | 1 |
| Sun, L | 1 |
| Yu, Z | 1 |
| Wu, B | 1 |
| Xiong, Y | 1 |
| Shi, Y | 1 |
| Qian, J | 1 |
| Zhang, F | 1 |
| Jia, B | 1 |
| Liu, X | 1 |
| Hu, Y | 1 |
| Zhang, Q | 1 |
| Yang, Y | 1 |
| Sun, D | 1 |
| Jiang, L | 1 |
| Simeone, R | 1 |
| Giacomello, R | 1 |
| Bruno, G | 1 |
| Parco, S | 1 |
| Maximova, N | 1 |
| Martinelli, M | 1 |
| Zito, G | 1 |
| Luppi, S | 1 |
| Cervi, G | 1 |
| Ricci, G | 1 |
| de Jong, PG | 2 |
| Kaandorp, S | 1 |
| Di Nisio, M | 1 |
| Goddijn, M | 3 |
| Middeldorp, S | 4 |
| Schindewolf, M | 1 |
| Recke, A | 1 |
| Zillikens, D | 1 |
| Lindhoff-Last, E | 2 |
| Ludwig, RJ | 1 |
| Mitić, G | 1 |
| Kovac, M | 1 |
| Povazan, L | 1 |
| Djordjević, V | 1 |
| Ilić, V | 1 |
| Salatić, I | 1 |
| Lazić, R | 1 |
| Antonijević, N | 1 |
| Novakov-Mikić, A | 1 |
| Kaandorp, SP | 1 |
| van der Post, JA | 1 |
| Hutten, BA | 2 |
| Verhoeve, HR | 2 |
| Hamulyák, K | 1 |
| Mol, BW | 3 |
| Folkeringa, N | 1 |
| Nahuis, M | 1 |
| Papatsonis, DN | 1 |
| Büller, HR | 1 |
| van der Veen, F | 1 |
| Greer, IA | 9 |
| Bednarek, W | 1 |
| Karowicz-Bilińska, A | 1 |
| Kotarski, J | 1 |
| Nowak-Markwitz, E | 1 |
| Oszukowski, P | 1 |
| Paszkowski, T | 1 |
| Poreba, R | 1 |
| Spaczyński, M | 1 |
| Teliga-Czajkowska, J | 1 |
| Snijder, CA | 1 |
| Cornette, JM | 1 |
| Hop, WC | 1 |
| Kruip, MJ | 1 |
| Duvekot, JJ | 1 |
| Makatsaria, AD | 1 |
| Bitsadze, VO | 1 |
| Dolgushina, NV | 1 |
| Lewandowski, K | 1 |
| Balcerzak, A | 1 |
| Kubiaczyk-Paluch, B | 1 |
| Breborowicz, GH | 1 |
| Obergfell, A | 1 |
| Langenfeld, H | 1 |
| Hopp, H | 1 |
| Steigerwald, U | 1 |
| Grossmann, R | 2 |
| Ruffatti, A | 2 |
| Favaro, M | 2 |
| Tonello, M | 2 |
| De Silvestro, G | 2 |
| Pengo, V | 2 |
| Fais, G | 1 |
| Suma, V | 1 |
| Chiarelli, S | 1 |
| Todesco, S | 1 |
| Jacquemyn, Y | 1 |
| Vercauteren, M | 1 |
| Myasnikova, VV | 2 |
| Galenko-Yaroshevskii, PA | 2 |
| Lysenkov, SP | 2 |
| Gigineishvili, MA | 1 |
| Berberashvili, TM | 1 |
| Kupreishvili, VZ | 1 |
| Rizhvadze, MR | 1 |
| Sukoyan, GV | 1 |
| Martinelli, P | 2 |
| Maruotti, GM | 1 |
| Coppola, A | 1 |
| Agangi, A | 1 |
| Paladini, D | 1 |
| Grandone, E | 4 |
| Di Minno, G | 2 |
| Marson, P | 1 |
| Bortolati, M | 1 |
| Minucci, D | 1 |
| Lee, JH | 1 |
| Park, NH | 1 |
| Keum, DY | 1 |
| Choi, SY | 1 |
| Kwon, KY | 1 |
| Cho, CH | 1 |
| Stojanovich, L | 1 |
| Mikovic, Z | 1 |
| Mandic, V | 1 |
| Popovich-Kuzmanovich, D | 1 |
| Schapkaitz, E | 1 |
| Jacobson, BF | 3 |
| Arnout, J | 1 |
| Spitz, B | 1 |
| Wittevrongel, C | 1 |
| Vanrusselt, M | 1 |
| Van Assche, A | 1 |
| Vermylen, J | 1 |
| Barkagan, ZS | 1 |
| Cyrkowicz, A | 1 |
| Rytwińska, E | 1 |
| Nytko, J | 1 |
| Słowińska-Zabówka, M | 1 |
| Llau, JV | 1 |
| Hoyas, L | 1 |
| Ezpeleta, J | 1 |
| García-Polit, J | 1 |
| Czestochowska, E | 1 |
| Arnaout, MS | 1 |
| Kazma, H | 1 |
| Khalil, A | 1 |
| Shasha, N | 1 |
| Nasrallah, A | 1 |
| Karam, K | 1 |
| Alam, SE | 1 |
| Boda, Z | 1 |
| László, P | 1 |
| Pfliegler, G | 1 |
| Tornai, I | 1 |
| Rejtö, L | 1 |
| Schlammadinger, A | 1 |
| Tam, WH | 1 |
| Wong, KS | 1 |
| Yuen, PM | 1 |
| Leung, TN | 1 |
| Li, CY | 1 |
| Iankova, Z | 2 |
| Bogdanova, M | 1 |
| Karag'ozova, Zh | 1 |
| Chernev, T | 1 |
| Baleva, M | 1 |
| Dimitrov, A | 1 |
| Mazarico, E | 2 |
| Peguero, A | 1 |
| Camprubí, M | 1 |
| Rovira, C | 1 |
| Gomez Roig, MD | 1 |
| Oros, D | 1 |
| Ibáñez-Burillo, P | 1 |
| Schoorlemmer, J | 1 |
| Masoller, N | 1 |
| Tàssies, MD | 1 |
| Figueras, F | 1 |
| Alalaf, SK | 1 |
| Jawad, RK | 1 |
| Muhammad, PR | 1 |
| Ali, MS | 1 |
| Al Tawil, NG | 1 |
| San Juan Alvarez, M | 1 |
| Márquez Garrido, G | 1 |
| Rodríguez Bertos, C | 1 |
| González Pérez, L | 1 |
| Fontcuberta Boj, J | 1 |
| Alalaf, S | 1 |
| Kalçık, M | 1 |
| Güner, A | 1 |
| Kalkan, S | 1 |
| Özkan, M | 1 |
| Kopuk, SY | 1 |
| Ozer, N | 1 |
| Cekmez, Y | 1 |
| Cakir, A | 1 |
| Gurkan, K | 1 |
| Tersigni, C | 3 |
| Maulucci, G | 1 |
| Castellani, R | 3 |
| Bianchetti, G | 1 |
| Onori, M | 1 |
| Franco, R | 1 |
| Barbaro, G | 1 |
| De Spirito, M | 1 |
| Lanzone, A | 1 |
| Scambia, G | 3 |
| Di Simone, N | 3 |
| Sacks, G | 1 |
| Zhang, J | 2 |
| Bruno, AM | 1 |
| Allshouse, AA | 1 |
| Campbell, HM | 1 |
| Branch, DW | 2 |
| Lim, MY | 1 |
| Silver, RM | 2 |
| Metz, TD | 1 |
| Jiang, Y | 2 |
| Zou, Q | 2 |
| Zhang, N | 2 |
| Chen, J | 2 |
| Chen, X | 2 |
| You, Q | 2 |
| Wu, H | 2 |
| Nasich, LL | 1 |
| Hoffman, R | 3 |
| Keren-Politansky, A | 1 |
| Jabareen, A | 1 |
| Kalish, Y | 3 |
| Schliamser, L | 1 |
| Brenner, B | 9 |
| Nadir, Y | 1 |
| Dabas, G | 1 |
| De, D | 1 |
| Handa, S | 1 |
| Aggarwal, D | 1 |
| Villani, M | 1 |
| Vecchione, G | 1 |
| Fischetti, L | 1 |
| Leccese, A | 1 |
| Santacroce, R | 1 |
| Corso, G | 1 |
| Margaglione, M | 3 |
| Rottenstreich, A | 2 |
| Gershgoren, H | 1 |
| Spectre, G | 1 |
| Da'as, N | 1 |
| Bentur, OS | 1 |
| Levin, G | 1 |
| Jacobson, B | 1 |
| Rambiritch, V | 1 |
| Paek, D | 1 |
| Sayre, T | 1 |
| Naidoo, P | 1 |
| Shan, J | 1 |
| Leisegang, R | 1 |
| Miyamoto, K | 1 |
| Komatsu, H | 1 |
| Nagaya, Y | 1 |
| Tsukihara, S | 1 |
| Sarugami, M | 1 |
| Osaku, D | 1 |
| Taniguchi, F | 1 |
| Harada, T | 1 |
| Kanamori, Y | 1 |
| Rahnemaei, FA | 1 |
| Fashami, MA | 1 |
| Abdi, F | 1 |
| Abbasi, M | 1 |
| Aleidan, FAS | 1 |
| Aljarba, GA | 1 |
| Aldakhil, AA | 1 |
| Allehyani, BI | 1 |
| Yahia, MA | 1 |
| Alghtani, NE | 1 |
| Badri, M | 1 |
| Alaklabi, AA | 1 |
| Alsuhaibani, A | 1 |
| Crowther, MA | 2 |
| Khodamoradi, Z | 1 |
| Boogar, SS | 1 |
| Shirazi, FKH | 1 |
| Kouhi, P | 1 |
| Chuzi, S | 1 |
| Eucalitto, P | 1 |
| Yee, LM | 1 |
| Serrano, F | 1 |
| Bisdorff-Bresson, A | 1 |
| Sroussi, J | 1 |
| Aymard, A | 1 |
| Wassef, M | 1 |
| Civelli, V | 1 |
| Boujlel, S | 1 |
| Houdart, E | 1 |
| Drouet, L | 1 |
| Rajaratnam, N | 1 |
| Patel, JP | 4 |
| Roberts, LN | 3 |
| Czuprynska, J | 1 |
| Patel, RK | 3 |
| Arya, R | 4 |
| Bouvier, S | 2 |
| Fortier, M | 1 |
| Vincent, L | 1 |
| Demattei, C | 1 |
| Mousty, E | 1 |
| Herzog, M | 1 |
| Rommelaere, G | 1 |
| Nouvellon, E | 1 |
| Mercier, E | 3 |
| Letouzey, V | 1 |
| Gris, JC | 10 |
| Llurba, E | 1 |
| Bella, M | 1 |
| Burgos, J | 1 |
| Gómez-Roig, MD | 1 |
| De Diego, R | 1 |
| Martínez-Astorquiza, T | 1 |
| Alijotas-Reig, J | 3 |
| Sánchez-Durán, MÁ | 1 |
| Sánchez, O | 2 |
| Carreras, E | 1 |
| Cabero, L | 1 |
| Shirazi, M | 1 |
| Naeiji, Z | 1 |
| Sharbaf, FR | 1 |
| Golshahi, F | 1 |
| Fathi, M | 1 |
| Nazari, F | 1 |
| Sahebdel, B | 1 |
| Farooqui, AB | 1 |
| Humbert, ML | 1 |
| Montague, MS | 1 |
| Doré, S | 1 |
| Simpkins, AN | 1 |
| Jerzak, M | 2 |
| Szafarowska, M | 1 |
| Kniotek, M | 1 |
| Gorski, A | 2 |
| Bolnick, AD | 1 |
| Bolnick, JM | 1 |
| Kohan-Ghadr, HR | 1 |
| Kilburn, BA | 1 |
| Pasalodos, OJ | 1 |
| Singhal, PK | 1 |
| Dai, J | 1 |
| Diamond, MP | 1 |
| Armant, DR | 1 |
| Drewlo, S | 1 |
| Senefonte, FRA | 1 |
| Aydos, RD | 2 |
| Oliveira, VM | 2 |
| Bósio, MAC | 1 |
| Figueiró-Filho, EA | 3 |
| Roueli, A | 1 |
| Cesario, E | 1 |
| Amsellem, J | 1 |
| Agman, A | 1 |
| Vauthier-Brouzes, D | 1 |
| Nizard, J | 1 |
| Shlomo, M | 1 |
| Gorodischer, R | 1 |
| Daniel, S | 1 |
| Wiznitzer, A | 1 |
| Matok, I | 1 |
| Fishman, B | 1 |
| Koren, G | 2 |
| Levy, A | 1 |
| Amsalem, H | 1 |
| Kleinstern, G | 1 |
| Burns, W | 1 |
| Koelper, N | 1 |
| Barberio, A | 1 |
| Deagostino-Kelly, M | 1 |
| Mennuti, M | 1 |
| Sammel, MD | 1 |
| Dugoff, L | 1 |
| Ozturk, G | 1 |
| Akpinar, P | 1 |
| Karamanlioglu, AD | 1 |
| Ozkan, FU | 1 |
| Aktas, I | 1 |
| Kumar Jha, R | 1 |
| Bansal, S | 1 |
| S Issar, H | 1 |
| Chaudhary, M | 1 |
| Sharma, S | 1 |
| Rashidi, F | 1 |
| Sate, H | 1 |
| Benatta, NF | 1 |
| Batouche, DD | 1 |
| Djazouli, MA | 1 |
| Vianello, A | 1 |
| Vencato, E | 1 |
| Cantini, M | 1 |
| Zanconato, G | 1 |
| Manfrin, E | 1 |
| Zamo, A | 1 |
| Zorzi, F | 1 |
| Mazzi, F | 1 |
| Martinelli, N | 1 |
| Cavaliere, E | 1 |
| Monari, F | 1 |
| Venturelli, D | 1 |
| Ferrara, F | 1 |
| Olivieri, O | 1 |
| De Franceschi, L | 1 |
| Eubanks, AA | 1 |
| Deering, SH | 1 |
| Thiel, LM | 1 |
| Einerson, BD | 1 |
| Hase, EA | 1 |
| Barros, VIPVL | 1 |
| Igai, AMK | 1 |
| Francisco, RPV | 1 |
| Zugaib, M | 1 |
| Guimicheva, B | 1 |
| Subramanian, D | 1 |
| Moriuchi, K | 1 |
| Chigusa, Y | 1 |
| Kondoh, E | 1 |
| Murakami, R | 1 |
| Ueda, Y | 1 |
| Mogami, H | 1 |
| Mandai, M | 1 |
| Garmi, G | 2 |
| Zafran, N | 1 |
| Okopnik, M | 1 |
| Gavish, I | 2 |
| Romano, S | 2 |
| Salim, R | 2 |
| Lin, T | 1 |
| Chen, Y | 2 |
| Cheng, X | 1 |
| Li, N | 1 |
| Sheng, X | 1 |
| Bailly, J | 1 |
| Louw, S | 1 |
| Liu, Y | 1 |
| Shan, N | 1 |
| Yuan, Y | 1 |
| Tan, B | 1 |
| Che, P | 1 |
| Qi, H | 1 |
| Solt, I | 1 |
| Ben David, C | 1 |
| Carp, H | 4 |
| Cox, S | 1 |
| Eslick, R | 1 |
| McLintock, C | 4 |
| Tardy, B | 1 |
| Buchmuller, A | 1 |
| Bistervels, IM | 1 |
| Ni Ainle, F | 2 |
| Oktem, M | 1 |
| Erdem, A | 1 |
| Demirdag, E | 1 |
| Cenksoy, C | 1 |
| Erdem, M | 1 |
| Bozkurt, N | 1 |
| Schaal, JV | 1 |
| Benhamou, D | 1 |
| Boyer, K | 1 |
| Mercier, FJ | 1 |
| Vijayan, V | 1 |
| Rachel, T | 1 |
| Siristatidis, C | 1 |
| Chrelias, C | 1 |
| Creatsa, M | 1 |
| Varounis, C | 1 |
| Vrachnis, N | 1 |
| Iliodromiti, Z | 1 |
| Kassanos, D | 1 |
| Lucania, G | 1 |
| Camiolo, E | 1 |
| Carmina, MG | 1 |
| Fiandaca, T | 1 |
| Indovina, A | 1 |
| Malato, A | 1 |
| Messina, R | 1 |
| Fabbiano, F | 1 |
| Marcenò, R | 1 |
| Bramham, K | 1 |
| Retter, A | 1 |
| Robinson, SE | 1 |
| Mitchell, M | 1 |
| Moore, GW | 1 |
| Hunt, BJ | 6 |
| Green, B | 3 |
| Marsh, MS | 2 |
| Davies, JG | 2 |
| Hiscock, RJ | 1 |
| Casey, E | 1 |
| Simmons, SW | 1 |
| Walker, SP | 1 |
| Newell, PA | 1 |
| Roberts, A | 1 |
| Cochery-Nouvellon, E | 2 |
| Lavigne-Lissalde, G | 2 |
| Marchetti, T | 1 |
| Balducchi, JP | 2 |
| Marès, P | 8 |
| Elmahashi, MO | 1 |
| Elbareg, AM | 1 |
| Essadi, FM | 1 |
| Ashur, BM | 1 |
| Adam, I | 1 |
| Darmochwał-Kolarz, D | 1 |
| Chara, A | 1 |
| Korzeniewski, M | 1 |
| Leszczyńska-Gorzelak, B | 1 |
| Oleszczuk, J | 1 |
| Hauck-Dlimi, B | 1 |
| Zimmermann, R | 1 |
| Eckstein, R | 1 |
| Ringwald, J | 1 |
| Mainini, G | 1 |
| Di Donna, MC | 1 |
| Esposito, E | 1 |
| Ercolano, S | 1 |
| Correa, R | 1 |
| Stradella, L | 1 |
| Della Gala, A | 1 |
| De Franciscis, P | 1 |
| Butwick, A | 1 |
| Hass, C | 1 |
| Wong, J | 1 |
| Lyell, D | 1 |
| El-Sayed, Y | 1 |
| Campbell, BK | 1 |
| Hernandez-Medrano, J | 1 |
| Onions, V | 1 |
| Pincott-Allen, C | 1 |
| Aljaser, F | 1 |
| Fisher, J | 1 |
| McNeilly, AS | 1 |
| Webb, R | 1 |
| Picton, HM | 1 |
| Senefonte, FR | 1 |
| Ferreira, CM | 2 |
| Pereira, EF | 1 |
| Menezes, GP | 1 |
| Bósio, MA | 1 |
| Königsbrügge, O | 1 |
| Langer, M | 1 |
| Hayde, M | 1 |
| Ay, C | 1 |
| Pabinger, I | 1 |
| Gysler, SM | 1 |
| Mulla, MJ | 1 |
| Stuhlman, M | 1 |
| Sfakianaki, AK | 1 |
| Paidas, MJ | 1 |
| Stanwood, NL | 1 |
| Gariepy, A | 1 |
| Brosens, JJ | 1 |
| Chamley, LW | 1 |
| Abrahams, VM | 1 |
| Ozdemir, D | 1 |
| Tam, AA | 1 |
| Dirikoc, A | 1 |
| Ersoy, R | 1 |
| Cakir, B | 1 |
| Ortigueira, M | 1 |
| Capanna, F | 1 |
| Boehlen, F | 1 |
| Martinez de Tejada, B | 1 |
| Savoldelli, G | 1 |
| Baker, RI | 1 |
| McGreor, SR | 1 |
| Tronina, O | 1 |
| Mikołajczyk, N | 1 |
| Pietrzak, B | 1 |
| Pacholczyk, M | 1 |
| Durlik, M | 1 |
| Martí-Gamboa, S | 1 |
| Savirón Cornudella, R | 1 |
| Campillos-Maza, JM | 1 |
| Pasquier, E | 1 |
| de Saint Martin, L | 1 |
| Bohec, C | 1 |
| Chauleur, C | 5 |
| Bretelle, F | 2 |
| Marhic, G | 1 |
| Le Gal, G | 2 |
| Debarge, V | 1 |
| Lecomte, F | 1 |
| Denoual-Ziad, C | 1 |
| Lejeune-Saada, V | 1 |
| Douvier, S | 1 |
| Heisert, M | 1 |
| Mottier, D | 1 |
| Rodger, MA | 5 |
| Quenby, S | 1 |
| Bloemenkamp, KW | 2 |
| Braams-Lisman, BA | 1 |
| de Bruin, JP | 1 |
| Coomarasamy, A | 1 |
| David, M | 3 |
| DeSancho, MT | 1 |
| van der Heijden, OW | 1 |
| Hoek, A | 1 |
| Jochmans, K | 1 |
| Koks, CA | 1 |
| Kuchenbecker, WK | 1 |
| Torrance, HL | 1 |
| Scheepers, HC | 1 |
| Stephenson, MD | 2 |
| Visser, J | 2 |
| de Vries, JI | 1 |
| Overcash, RT | 1 |
| Somers, AT | 1 |
| LaCoursiere, DY | 1 |
| Rosengarten, D | 1 |
| Kramer, R | 1 |
| Stephenson, ML | 1 |
| Serra, AE | 1 |
| Neeper, JM | 1 |
| Caballero, DC | 1 |
| McNulty, J | 1 |
| Ismail, AM | 1 |
| Hamed, AH | 1 |
| Saso, S | 1 |
| Abu-Elhasan, AM | 1 |
| Abu-Elghar, MM | 1 |
| Abdelmeged, AN | 1 |
| Petrie, S | 1 |
| Barras, M | 1 |
| Lust, K | 1 |
| Fagermo, N | 1 |
| Allen, J | 1 |
| Martin, JH | 1 |
| Mastrolia, SA | 1 |
| Novack, L | 1 |
| Thachil, J | 1 |
| Rabinovich, A | 1 |
| Pikovsky, O | 1 |
| Klaitman, V | 1 |
| Loverro, G | 1 |
| Erez, O | 1 |
| Nachum, Z | 1 |
| Braverman, M | 1 |
| Lefkou, E | 2 |
| Mamopoulos, A | 1 |
| Dagklis, T | 1 |
| Vosnakis, C | 1 |
| Rousso, D | 1 |
| Girardi, G | 1 |
| Raheemullah, A | 1 |
| Laurence, TN | 1 |
| Fernández-Alba, JJ | 1 |
| González-Macías, C | 1 |
| Vilar Sánchez, A | 1 |
| Tajada Cepero, P | 1 |
| Garrido Teruel, R | 1 |
| García-Cabanillas, MJ | 1 |
| Moreno-Corral, LJ | 1 |
| Torrejón Cardoso, R | 1 |
| Haddad, B | 3 |
| Winer, N | 1 |
| Chitrit, Y | 1 |
| Houfflin-Debarge, V | 1 |
| Bages, K | 1 |
| Tsatsaris, V | 1 |
| Benachi, A | 1 |
| Bastuji-Garin, S | 1 |
| Nahas, R | 1 |
| Saliba, W | 1 |
| Elias, A | 1 |
| Elias, M | 1 |
| Demers, S | 1 |
| Bujold, E | 1 |
| Roberge, S | 1 |
| Narin, C | 1 |
| Reyhanoglu, H | 1 |
| Tülek, B | 1 |
| Onoglu, R | 1 |
| Ege, E | 1 |
| Sarigül, A | 1 |
| Yeniterzi, M | 1 |
| Durmaz, I | 1 |
| Casellas-Caro, M | 1 |
| Ferrer-Oliveras, R | 1 |
| Llurba-Olive, E | 1 |
| Hermosilla, E | 1 |
| Vilardell-Tarres, M | 1 |
| Cabero-Roura, L | 1 |
| Fox, NS | 1 |
| Laughon, SK | 1 |
| Bender, SD | 1 |
| Saltzman, DH | 1 |
| Rebarber, A | 1 |
| Bernardon, M | 1 |
| Limone, A | 1 |
| Businelli, C | 1 |
| Maso, GP | 1 |
| Piccoli, M | 1 |
| Alberico, S | 1 |
| Qublan, H | 1 |
| Amarin, Z | 1 |
| Dabbas, M | 1 |
| Farraj, AE | 1 |
| Beni-Merei, Z | 1 |
| Al-Akash, H | 1 |
| Bdoor, AN | 1 |
| Nawasreh, M | 1 |
| Malkawi, S | 1 |
| Diab, F | 1 |
| Al-Ahmad, N | 1 |
| Balawneh, M | 1 |
| Abu-Salim, A | 1 |
| Ramidi, G | 1 |
| Khan, N | 2 |
| Glueck, CJ | 3 |
| Wang, P | 3 |
| Goldenberg, N | 2 |
| Forsnes, E | 1 |
| Occhino, A | 1 |
| Acosta, R | 1 |
| Dawley, B | 1 |
| Hendrix, A | 1 |
| Stefanidis, K | 1 |
| Papoutsis, D | 1 |
| Daskalakis, G | 1 |
| Loutradis, D | 1 |
| Antsaklis, A | 1 |
| Borahay, MA | 1 |
| Kelly, BC | 1 |
| Harirah, HM | 1 |
| Miesbach, W | 1 |
| Galanakis, D | 1 |
| Scharrer, I | 1 |
| Ruiz-Irastorza, G | 1 |
| Martinez-Berriotxoa, A | 1 |
| Egurbide, MV | 1 |
| Salomon, O | 1 |
| Dulitzky, M | 1 |
| Apter, S | 1 |
| McCowan, LM | 2 |
| North, RA | 4 |
| Winger, EE | 2 |
| Reed, JL | 2 |
| Mo, D | 1 |
| Saravelos, S | 1 |
| Metwally, M | 1 |
| Makris, M | 1 |
| Li, TC | 1 |
| Friedrich, E | 1 |
| Hameed, AB | 1 |
| Meneveau, N | 1 |
| Panni, JK | 1 |
| Panni, MK | 1 |
| Niemiec, T | 1 |
| Nowakowska, A | 1 |
| Klochowicz, M | 1 |
| Baranowski, W | 1 |
| Clark, P | 1 |
| Walker, ID | 5 |
| Langhorne, P | 1 |
| Crichton, L | 1 |
| Thomson, A | 1 |
| Greaves, M | 1 |
| Whyte, S | 1 |
| Tonbul, A | 1 |
| Uras, N | 1 |
| Tayman, C | 1 |
| Halici, T | 1 |
| Polat, A | 1 |
| Mansur Tatli, M | 1 |
| Kini, U | 1 |
| Hurst, JA | 1 |
| Byren, JC | 1 |
| Wall, SA | 1 |
| Johnson, D | 1 |
| Wilkie, AO | 1 |
| Fernández, E | 1 |
| Dueñas, N | 1 |
| Villafranca, A | 1 |
| Perea, M | 1 |
| Amorós, B | 1 |
| Bermejo, L | 1 |
| Saeed, CR | 1 |
| Pravin, M | 1 |
| Aziz, RH | 1 |
| Serasheini, M | 1 |
| Dominique, TG | 1 |
| Junovich, G | 1 |
| Dubinsky, V | 1 |
| Gentile, T | 1 |
| Sarto, A | 2 |
| Pasqualini, S | 1 |
| Gutiérrez, G | 1 |
| Sudrová, M | 1 |
| Kvasnička, J | 1 |
| Kudrnová, Z | 1 |
| Zenáhlíková, Z | 1 |
| Mazoch, J | 1 |
| Brzežková, R | 1 |
| Faillie, JL | 1 |
| Baer, G | 1 |
| Fabbro-Peray, P | 2 |
| Quéré, I | 4 |
| Lefrant, JY | 2 |
| Dauzat, M | 3 |
| Akcay, AB | 1 |
| Yuce, M | 1 |
| Akcay, M | 1 |
| Sen, N | 1 |
| Soydinc, HE | 1 |
| Davutoglu, V | 1 |
| Hajj-Chahine, J | 1 |
| Jayle, C | 1 |
| Tomasi, J | 1 |
| Corbi, P | 1 |
| Sachithanandan, A | 1 |
| Pranikoff, J | 1 |
| Riaz, K | 1 |
| Chavan, K | 1 |
| Raj, P | 1 |
| Umar, M | 1 |
| Ulander, VM | 3 |
| Helmerhorst, FM | 1 |
| Lampinen, K | 1 |
| Morin-Papunen, L | 1 |
| Kaaja, RJ | 2 |
| Fouda, UM | 2 |
| Sayed, AM | 2 |
| Ramadan, DI | 2 |
| Fouda, IM | 2 |
| Sucak, A | 1 |
| Acar, K | 1 |
| Celen, S | 1 |
| Danisman, N | 1 |
| Sucak, GT | 1 |
| Fatima, S | 1 |
| Watson, J | 1 |
| Douek, I | 1 |
| Fox, R | 1 |
| Amagada, JO | 1 |
| Pembridge, J | 1 |
| Kupferminc, MJ | 2 |
| Rimon, E | 1 |
| Many, A | 5 |
| Sharon, M | 1 |
| Lessing, JB | 2 |
| Gamzu, R | 1 |
| Berker, B | 1 |
| Taşkin, S | 1 |
| Kahraman, K | 1 |
| Taşkin, EA | 1 |
| Atabekoğlu, C | 1 |
| Sönmezer, M | 1 |
| Abdou, AM | 1 |
| Zaki, MM | 1 |
| Misra, D | 1 |
| Aledort, L | 1 |
| Stock, SJ | 1 |
| Walker, MC | 1 |
| Edelshain, BT | 1 |
| Horn, L | 1 |
| Norman, JE | 1 |
| Denison, FC | 1 |
| Ashoush, S | 1 |
| El-Toukhy, T | 1 |
| Ahuja, S | 1 |
| Taranissi, M | 1 |
| Shapiro, NL | 1 |
| Kominiarek, MA | 1 |
| Nutescu, EA | 1 |
| Chevalier, AB | 1 |
| Hibbard, JU | 1 |
| Molinari, N | 1 |
| Cuerva-González, MJ | 1 |
| Lacoponi, S | 1 |
| de la Calle-Fernández, M | 1 |
| Pozo-Krielinger, J | 1 |
| Ciçek Yilmaz, D | 1 |
| Büyükakilli, B | 1 |
| Yilmaz, AR | 1 |
| Gürgül, S | 1 |
| Di Nicuolo, F | 2 |
| Veglia, M | 1 |
| Silano, M | 1 |
| Tritarelli, A | 1 |
| Marana, R | 2 |
| Smith, JS | 1 |
| Mueller, J | 1 |
| Daniels, CJ | 1 |
| Wu, XX | 1 |
| Tan, JP | 1 |
| Liu, ML | 1 |
| Liu, YL | 1 |
| Zhang, JP | 1 |
| van Hasselt, JG | 1 |
| Morrish, GA | 1 |
| Ng, WP | 1 |
| Yip, WL | 1 |
| Macafee, B | 1 |
| Campbell, JP | 1 |
| Ashpole, K | 1 |
| Cox, M | 1 |
| Matthey, F | 1 |
| Acton, L | 1 |
| Yentis, SM | 1 |
| Bashiri, A | 1 |
| Ratzon, R | 1 |
| Amar, S | 1 |
| Serjienko, R | 1 |
| Mazor, M | 1 |
| Shoham-Vardi, I | 1 |
| Kahn, SR | 7 |
| Springmann, V | 1 |
| Schulman, S | 1 |
| Martineau, J | 1 |
| Stewart, JA | 1 |
| Komari, N | 1 |
| McLeod, A | 2 |
| Strulovitch, C | 1 |
| Blostein, M | 2 |
| Faucher, JP | 1 |
| Gamble, G | 1 |
| Gordon, W | 1 |
| Kagoma, PK | 1 |
| Miron, MJ | 1 |
| Laverdière, D | 1 |
| Game, M | 1 |
| Mills, A | 1 |
| D'Ippolito, S | 1 |
| Stinson, J | 2 |
| de Oliveira, VM | 1 |
| Breda, I | 1 |
| Coelho, LR | 1 |
| Brancaccio, V | 1 |
| Colaizzo, D | 2 |
| Sciannamé, N | 1 |
| Pavone, G | 1 |
| Kaul, B | 1 |
| Vallejo, MC | 1 |
| Ramanathan, S | 1 |
| Mandell, GL | 1 |
| Krohner, RG | 1 |
| Bergmann, JF | 1 |
| Mouly, S | 1 |
| Lagrange, F | 2 |
| Brun, JL | 2 |
| Vergnes, MC | 1 |
| Paolucci, F | 2 |
| Nadal, T | 2 |
| Leng, JJ | 2 |
| Saux, MC | 2 |
| Bannwarth, B | 1 |
| Izaguirre, R | 1 |
| De La Peña, A | 1 |
| Ramírez, A | 1 |
| Cortina, E | 1 |
| Huerta, M | 1 |
| Salazar, E | 1 |
| Ginsberg, JS | 1 |
| Chan, WS | 2 |
| Bates, SM | 1 |
| Kaatz, S | 1 |
| Konkle, BA | 2 |
| Bauer, KA | 2 |
| Weinstein, R | 1 |
| Greist, A | 1 |
| Holmes, HE | 1 |
| Bonfiglio, J | 1 |
| Dolitzky, M | 2 |
| Inbal, A | 2 |
| Fareed, J | 1 |
| Hoppensteadt, D | 1 |
| Walenga, J | 1 |
| Iqbal, O | 1 |
| Ma, Q | 1 |
| Jeske, W | 1 |
| Sheikh, T | 1 |
| Topol, EJ | 1 |
| Blickstein, D | 1 |
| Hod, M | 1 |
| Bar, J | 2 |
| White, HD | 1 |
| Rowan, JA | 2 |
| Taylor, RS | 1 |
| Hoffet, M | 2 |
| Ripart-Neveu, S | 1 |
| Tailland, ML | 2 |
| Ferrer-Raventos, JC | 1 |
| Bird, H | 1 |
| Kapoor, V | 1 |
| Vallance, H | 1 |
| Kujovich, JL | 1 |
| Gaiser, RR | 1 |
| Berkowitz, DH | 1 |
| Chou, D | 1 |
| Sieve, L | 1 |
| Gates, S | 1 |
| Brocklehurst, P | 1 |
| Ayers, S | 1 |
| Bowler, U | 1 |
| Boedeker, CC | 1 |
| Ridder, GJ | 1 |
| Weerda, N | 1 |
| Maier, W | 1 |
| Klenzner, T | 1 |
| Schipper, J | 1 |
| Lindqvist, PG | 5 |
| Merlo, J | 2 |
| Dulitsky, M | 1 |
| Younis, J | 1 |
| Maslovitz, S | 1 |
| Landsberg, JA | 1 |
| Varon, D | 2 |
| Huxtable, LM | 1 |
| Tafreshi, MJ | 1 |
| Ondreyco, SM | 1 |
| Seshadri, N | 1 |
| Goldhaber, SZ | 1 |
| Elkayam, U | 1 |
| Grimm, RA | 1 |
| Groce, JB | 1 |
| Heit, JA | 1 |
| Spinler, SA | 1 |
| Turpie, AG | 1 |
| Bosker, G | 1 |
| Klein, AL | 1 |
| Ellis, M | 1 |
| Yarom, I | 1 |
| Yohai, D | 1 |
| Samueloff, A | 1 |
| Aharon, A | 1 |
| Lanir, N | 3 |
| Drugan, A | 1 |
| Joffe, GM | 1 |
| Aisenbrey, GA | 1 |
| Argubright, KF | 1 |
| Sarig, G | 1 |
| Blumenfeld, Z | 2 |
| Leiba, R | 1 |
| Thamban, S | 1 |
| Opemuyi, IO | 1 |
| Swinhoe, JR | 1 |
| Cochrane, GW | 1 |
| Monastiri, K | 1 |
| Seket, B | 1 |
| Chouchane, S | 1 |
| Samama, MM | 1 |
| Mahjoub, T | 1 |
| De Carolis, S | 1 |
| Ferrazzani, S | 1 |
| De Stefano, V | 2 |
| Garofalo, S | 1 |
| Fatigante, G | 1 |
| Rossi, E | 2 |
| Leone, G | 1 |
| Caruso, A | 1 |
| Bischoff, A | 1 |
| Brügger-Andersen, T | 1 |
| Hetland, Ø | 1 |
| Pönitz, V | 1 |
| Grundt, H | 1 |
| Nilsen, DW | 1 |
| Segal, Y | 1 |
| Weiss, A | 1 |
| Erden, O | 1 |
| Imir, A | 1 |
| Guvenal, T | 1 |
| Muslehiddinoglu, A | 1 |
| Arici, S | 1 |
| Cetin, M | 1 |
| Cetin, A | 1 |
| Casele, H | 1 |
| Haney, EI | 1 |
| James, A | 1 |
| Rosene-Montella, K | 2 |
| Carson, M | 1 |
| Lee, RH | 1 |
| Goodwin, TM | 1 |
| Carroll, RC | 1 |
| Craft, RM | 1 |
| Whitaker, GL | 1 |
| Snider, CC | 1 |
| Kirby, RK | 1 |
| Elder, RF | 1 |
| Hennessey, MD | 1 |
| Elchalal, U | 1 |
| Gabbay, E | 1 |
| Nadjari, M | 1 |
| Zelig, O | 1 |
| Ben-Chetrit, E | 1 |
| Puértolas Ortega, M | 1 |
| Izquierdo Villarroya, B | 1 |
| Oliva Perales, P | 1 |
| Lafuente Ojeda, N | 1 |
| Izquierdo Villarroya, J | 1 |
| Ruiz Pérez, R | 1 |
| Santoro, R | 1 |
| Iannaccaro, P | 1 |
| Sottilotta, G | 1 |
| Kenny, B | 1 |
| Volobuev, V | 1 |
| Ajayi, AA | 1 |
| Pharmacols, FB | 1 |
| Cooper, J | 1 |
| Horn, EH | 1 |
| Rubin, PC | 1 |
| Fawzy, M | 1 |
| Shokeir, T | 1 |
| El-Tatongy, M | 1 |
| Warda, O | 1 |
| El-Refaiey, AA | 1 |
| Mosbah, A | 1 |
| Kinori, M | 1 |
| Saar, N | 1 |
| Justo, D | 1 |
| Almog, R | 1 |
| Freedman, RA | 1 |
| Neuberg, DS | 1 |
| Zwicker, JI | 1 |
| Bick, RL | 2 |
| Quenet, S | 1 |
| Varlet, MN | 1 |
| Seffert, P | 1 |
| Laporte, S | 1 |
| Decousus, H | 1 |
| Mismetti, P | 1 |
| Camacho Pulido, JA | 1 |
| Jiménez Sánchez, JM | 1 |
| Montijano Vizcaíno, A | 1 |
| Jurado Lara, B | 1 |
| de Molina Ortega, A | 1 |
| Cappucci, F | 1 |
| Fernández-Meré, LA | 1 |
| Fernández Rogríguez, S | 1 |
| Alvarez-Blanco, M | 1 |
| Lebaudy, C | 1 |
| Hulot, JS | 1 |
| Amoura, Z | 1 |
| Costedoat-Chalumeau, N | 1 |
| Serreau, R | 1 |
| Ankri, A | 1 |
| Conard, J | 2 |
| Cornet, A | 1 |
| Dommergues, M | 1 |
| Piette, JC | 1 |
| Lechat, P | 1 |
| Luzardo, GE | 1 |
| Karlnoski, RA | 1 |
| Williams, B | 1 |
| Mangar, D | 1 |
| Camporesi, EM | 1 |
| Neveu, S | 1 |
| Courtieu, C | 1 |
| Schved, JF | 2 |
| Fejgin, MD | 1 |
| Lourwood, DL | 1 |
| Nelson-Piercy, C | 5 |
| Sturridge, F | 1 |
| de Swiet, M | 2 |
| Letsky, E | 1 |
| Phillips, JK | 1 |
| Majumdar, G | 2 |
| Savidge, GF | 2 |
| Macklon, NS | 1 |
| Reid, AW | 1 |
| Dulitzki, M | 2 |
| Pauzner, R | 2 |
| Langevitz, P | 2 |
| Pras, M | 1 |
| Schiff, E | 1 |
| Guillonneau, M | 1 |
| de Crepy, A | 1 |
| Aufrant, C | 1 |
| Hurtaud-Roux, MF | 1 |
| Jacqz-Aigrain, E | 1 |
| Letsky, EA | 1 |
| Ellis, MH | 2 |
| Nun, IB | 1 |
| Rathaus, V | 1 |
| Werner, M | 1 |
| Shenkman, L | 1 |
| Finkelstein, Y | 1 |
| Aloni, D | 1 |
| Kimia, A | 1 |
| Sommer, R | 1 |
| Sirota, L | 1 |
| Brennand, JE | 1 |
| Casele, HL | 1 |
| Laifer, SA | 1 |
| Woelkers, DA | 1 |
| Venkataramanan, R | 1 |
| Stephan, D | 1 |
| Welsch, M | 1 |
| Chapatte, D | 1 |
| Weltin, D | 1 |
| Imbs, JL | 1 |
| Bonnar, J | 4 |
| Norris, LA | 4 |
| Greene, R | 1 |
| Barjot, P | 1 |
| Beucher, G | 1 |
| Le Querrec, A | 1 |
| Derlon-Borel, A | 1 |
| Herlicoviez, M | 1 |
| Manor, Y | 1 |
| Witz, M | 1 |
| Lev-Ran, O | 1 |
| Kramer, A | 1 |
| Gurevitch, J | 1 |
| Shapira, I | 1 |
| Mohr, R | 1 |
| Younis, JS | 2 |
| Ohel, G | 1 |
| Haddad, S | 1 |
| Ben-Ami, M | 1 |
| Weiner, Z | 1 |
| Dahlbäck, B | 1 |
| Rocha, E | 1 |
| Panizo, C | 1 |
| Lecumberri, R | 1 |
| Ellison, J | 3 |
| Berndt, N | 1 |
| Khan, I | 1 |
| Gallo, R | 1 |
| Magdelaine, A | 1 |
| Verdy, E | 1 |
| Coulet, F | 1 |
| Berkane, N | 1 |
| Girot, R | 1 |
| Uzan, S | 1 |
| Soubrier, F | 1 |
| Harrison, SJ | 1 |
| Rafferty, I | 1 |
| McColl, MD | 1 |
| Oles, D | 1 |
| Berryessa, R | 1 |
| Campbell, K | 1 |
| Bhatti, MA | 1 |
| Dzialo, AF | 1 |
| Black-Schaffer, RM | 1 |
| Thomson, AJ | 2 |
| Bagga, R | 1 |
| Sawhney, H | 1 |
| Saxena, SV | 1 |
| Aggarwal, N | 1 |
| Vasishta, K | 1 |
| Rocha, M | 1 |
| Geller, M | 1 |
| Capmany, C | 1 |
| Martínez, M | 1 |
| Quintans, C | 1 |
| Donaldson, M | 1 |
| Pasqualini, RS | 1 |
| Raudkivi, PJ | 1 |
| Lepercq, J | 1 |
| Borel-Derlon, A | 1 |
| Darmon, JY | 1 |
| Boudignat, O | 1 |
| Francoual, C | 1 |
| Priollet, P | 1 |
| Cohen, C | 1 |
| Yvelin, N | 1 |
| Tournaire, M | 1 |
| Borg, JY | 2 |
| Conkie, JA | 1 |
| McCall, F | 1 |
| Walker, D | 1 |
| Greer, A | 1 |
| Livneh, A | 1 |
| Kenett, R | 1 |
| Vergnes, C | 1 |
| Banwarth, B | 1 |
| Spitzer, K | 1 |
| Julian, J | 1 |
| Ginsberg, J | 1 |
| Johnston, M | 1 |
| Crowther, R | 1 |
| Laskin, C | 1 |
| Wellington, K | 1 |
| McClellan, K | 1 |
| Jarvis, B | 2 |
| Breddin, HK | 1 |
| Xiao, S | 1 |
| Luo, Y | 1 |
| Guo, L | 1 |
| Mu, L | 1 |
| Ye, Z | 1 |
| Novak, P | 1 |
| Novak, A | 1 |
| Šabović, M | 1 |
| Kozak, M | 1 |
| Wat, JM | 2 |
| Baczyk, D | 2 |
| Kingdom, JC | 2 |
| Abdulghani, S | 1 |
| Moretti, F | 1 |
| Gruslin, A | 1 |
| Grynspan, D | 1 |
| Askim, AJ | 1 |
| Thrane, AS | 1 |
| Giaever, P | 1 |
| Andersen, R | 1 |
| Krohn, J | 1 |
| Hawrylyshyn, K | 1 |
| Greig, IR | 1 |
| Xiang, Y | 1 |
| Li, J | 1 |
| Sun, Y | 1 |
| Hellgren, M | 5 |
| Mistafa, O | 1 |
| Kleppa, MJ | 1 |
| Erlenwein, SV | 1 |
| Darashchonak, N | 1 |
| von Kaisenberg, CS | 1 |
| von Versen-Höynck, F | 1 |
| Hecking, C | 1 |
| Hendelmeier, M | 1 |
| von Bardeleben, R | 1 |
| Gröschel, K | 1 |
| Schinzel, H | 3 |
| Gibson, PS | 2 |
| Nerenberg, KA | 1 |
| Hague, WM | 3 |
| Kingdom, J | 3 |
| Karovitch, A | 1 |
| Sermer, M | 2 |
| Clement, AM | 3 |
| Coat, S | 1 |
| Said, J | 1 |
| Rey, E | 5 |
| Robinson, S | 1 |
| Khurana, R | 2 |
| Demers, C | 2 |
| Kovacs, MJ | 3 |
| Solymoss, S | 2 |
| Hinshaw, K | 1 |
| Dwyer, J | 1 |
| Smith, G | 1 |
| McDonald, S | 1 |
| Newstead-Angel, J | 1 |
| Khandelwal, M | 1 |
| Keely, E | 1 |
| Walker, M | 1 |
| Wells, PS | 2 |
| Phillips, P | 1 |
| James, AH | 1 |
| Ferrazzi, EM | 1 |
| Gervasi, MT | 1 |
| Simioni, P | 1 |
| Seed, PT | 2 |
| Schleussner, E | 1 |
| Kamin, G | 1 |
| Seliger, G | 1 |
| Rogenhofer, N | 1 |
| Ebner, S | 1 |
| Toth, B | 1 |
| Schenk, M | 1 |
| Henes, M | 1 |
| Bohlmann, MK | 1 |
| Fischer, T | 2 |
| Brosteanu, O | 1 |
| Bauersachs, R | 2 |
| Petroff, D | 1 |
| Luna, RL | 1 |
| Vasconcelos, AG | 1 |
| Nunes, AK | 1 |
| de Oliveira, WH | 1 |
| Barbosa, KP | 1 |
| Peixoto, CA | 1 |
| Chow, L | 1 |
| Carr, A | 1 |
| MacKenzie, L | 1 |
| Walker, A | 1 |
| Archer, D | 1 |
| Lee, A | 1 |
| Vanderbeke, I | 1 |
| Boll, D | 1 |
| Verguts, JK | 1 |
| Gerdsen, F | 1 |
| Luxembourg, B | 1 |
| Langer, F | 1 |
| Garneau, P | 1 |
| Gauthier, R | 1 |
| Leduc, L | 2 |
| Michon, N | 1 |
| Morin, F | 1 |
| Magee, LA | 1 |
| Rodger, M | 3 |
| Henrich, W | 1 |
| Onügören, O | 1 |
| Kivelitz, D | 1 |
| Dudenhausen, JW | 1 |
| Ekman-Ordeberg, G | 2 |
| Akerud, A | 2 |
| Andersson, E | 1 |
| Dubicke, A | 2 |
| Sennstrom, M | 1 |
| Byström, B | 1 |
| Tzortzatos, G | 1 |
| Gomez, MF | 1 |
| Edlund, M | 1 |
| Lindahl, U | 1 |
| Malmström, A | 2 |
| Monien, S | 1 |
| Kadecki, O | 1 |
| Baumgarten, S | 1 |
| Salama, A | 1 |
| Dörner, T | 1 |
| Kiesewetter, H | 1 |
| Andersen, AS | 1 |
| Berthelsen, JG | 1 |
| Bergholt, T | 1 |
| Isma, N | 1 |
| Svensson, PJ | 1 |
| Lindblad, B | 1 |
| Gredilla, E | 1 |
| Pérez-Ferrer, A | 1 |
| Canser, E | 1 |
| Alonso, E | 1 |
| Martínez Serrano, B | 1 |
| Gilsanz, F | 1 |
| Noci, I | 1 |
| Milanini, MN | 1 |
| Ruggiero, M | 1 |
| Papini, F | 1 |
| Fuzzi, B | 1 |
| Artini, PG | 1 |
| Norrad, RS | 1 |
| Salehian, O | 1 |
| Kalu, E | 1 |
| Wayne, C | 1 |
| Croucher, C | 1 |
| Findley, I | 1 |
| Manyonda, I | 1 |
| Eldor, A | 1 |
| Stenqvist, P | 1 |
| Kaaja, R | 4 |
| Ebina, Y | 1 |
| Yamada, H | 1 |
| Kato, EH | 1 |
| Yamamoto, R | 1 |
| Sakuragi, N | 1 |
| Fujimoto, S | 1 |
| Stone, S | 1 |
| Parmar, K | 1 |
| Khamashta, MA | 1 |
| Poston, L | 1 |
| Jacobsen, AF | 1 |
| Qvigstad, E | 1 |
| Sandset, PM | 1 |
| Sephton, V | 1 |
| Farquharson, RG | 2 |
| Topping, J | 1 |
| Quenby, SM | 1 |
| Cowan, C | 1 |
| Back, DJ | 1 |
| Toh, CH | 1 |
| Gattens, M | 1 |
| Khamashta, M | 2 |
| Almeida, A | 1 |
| Ballem, PJ | 1 |
| Tsang, P | 1 |
| Purkiss, S | 1 |
| Ensworth, S | 1 |
| Houlihan, E | 1 |
| Ensom, MH | 1 |
| Barbour, LA | 1 |
| Oja, JL | 1 |
| Schultz, LK | 1 |
| Mello, G | 1 |
| Parretti, E | 1 |
| Fatini, C | 1 |
| Riviello, C | 1 |
| Gensini, F | 1 |
| Marchionni, M | 1 |
| Scarselli, GF | 1 |
| Gensini, GF | 1 |
| Abbate, R | 1 |
| Hirota, Y | 1 |
| Sakai, M | 1 |
| Nakabayashi, M | 1 |
| Abou-Nassar, K | 1 |
| Wells, P | 1 |
| Doucette, S | 1 |
| Ramsay, T | 1 |
| Mackinnon, K | 1 |
| Cranney, A | 1 |
| Hodsman, A | 1 |
| Lazo-Langner, A | 1 |
| Heilmann, L | 1 |
| Rath, W | 2 |
| Pollow, K | 1 |
| Dubois, E | 1 |
| Takser, L | 1 |
| Krafft, A | 1 |
| Bauersachs, RM | 1 |
| Dudenhausen, J | 1 |
| Faridi, A | 1 |
| Fung, S | 1 |
| Geisen, U | 2 |
| Harenberg, J | 2 |
| Herchenhan, E | 1 |
| Keller, F | 2 |
| Kemkes-Matthes, B | 1 |
| Spannagl, M | 1 |
| Thaler, CJ | 1 |
| Herzog, S | 1 |
| Kuhn, W | 1 |
| Shefras, J | 1 |
| Doughty, HA | 1 |
| Copplestone, A | 1 |
| Kerslake, S | 1 |
| Buchanan, N | 1 |
| Hughes, G | 1 |
| Rowlands, S | 1 |
| Lahoud, R | 1 |
| Hertzberg, M | 1 |
| Nicholl, M | 1 |
| Drouet, M | 1 |
| Le Sellin, J | 1 |
| Sabbah, A | 1 |
| Blombäck, M | 4 |
| Bremme, K | 4 |
| Siegbahn, A | 1 |
| Lindberg, H | 2 |
| Pettilä, V | 3 |
| Leinonen, P | 3 |
| Ekblad, U | 1 |
| Kataja, M | 1 |
| Ikkala, E | 1 |
| Huhle, G | 1 |
| Geberth, M | 1 |
| Hoffmann, U | 1 |
| Heene, DL | 1 |
| Trott, EA | 1 |
| Trott, AM | 1 |
| Dunn, CJ | 2 |
| Chung, TS | 1 |
| Kim, SC | 1 |
| Rivard, GE | 1 |
| van Rooijen, M | 1 |
| Yu, A | 1 |
| Moll, S | 1 |
| Schambeck, CM | 1 |
| Eberl, E | 1 |
| Ylikorkala, O | 1 |
| Taylor, AA | 1 |
| Markkola, A | 1 |
| Hiilesmaa, V | 1 |
| Antovic, A | 1 |
| He, S | 1 |
| Bahlmann, F | 1 |
| Peetz, D | 1 |
| Savvidis, S | 1 |
| Himmrich, L | 1 |
| Klotz, M | 1 |
| Amerali, M | 1 |
| Politou, M | 1 |
| Maguire, PJ | 1 |
| McGuire, M | 1 |
| Power, KA | 1 |
| McNicholl, M | 1 |
| Sheehan, SR | 1 |
| Turner, MJ | 1 |
| Østergaard, S | 1 |
| Hvas, AM | 1 |
| Medrud, L | 1 |
| Fuglsang, J | 1 |
| Khalifeh, A | 1 |
| Grantham, J | 1 |
| Byrne, J | 1 |
| Murphy, K | 2 |
| McAuliffe, F | 2 |
| Byrne, B | 2 |
| Ismail, SK | 2 |
| Norris, L | 2 |
| O'Shea, S | 1 |
| Higgins, JR | 2 |
| Parent, F | 1 |
| Deruelle, P | 1 |
| Meyer, G | 1 |
| Girard, P | 1 |
| Jilwan, F | 1 |
| Boyer-Neumann, C | 1 |
| Wolf, M | 1 |
| Simonneau, G | 1 |
| Shaaban, OM | 1 |
| Abbas, AM | 1 |
| Zahran, KM | 1 |
| Fathalla, MM | 1 |
| Anan, MA | 1 |
| Salman, SA | 1 |
| Griffiths, S | 1 |
| Woo, C | 1 |
| Mansoubi, V | 1 |
| Riccoboni, A | 1 |
| Sabharwal, A | 1 |
| Napier, S | 1 |
| Columb, M | 1 |
| Laffan, M | 1 |
| Stocks, G | 1 |
| Wong, A | 1 |
| Appleby, N | 1 |
| Regan, C | 1 |
| Hassan, T | 1 |
| Milner, M | 1 |
| Sullivan, AO | 1 |
| White, B | 1 |
| O'Donnell, J | 1 |
| Lykke, JA | 1 |
| Grønlykke, T | 1 |
| Langhoff-Roos, J | 2 |
| Higgins, M | 1 |
| Downey, R | 1 |
| Jensen, HH | 1 |
| Søgaard, K | 1 |
| Grande, P | 1 |
| Powrie, R | 1 |
| Talbot, DJ | 1 |
| Muttukrishna, S | 1 |
| Newell, K | 1 |
| Sam, DX | 1 |
| Mansoor, A | 1 |
| Jiang, X | 1 |
| Tang, S | 1 |
| Ross, S | 1 |
| Backe, SK | 1 |
| Lyons, GR | 1 |
| Pineo, GF | 1 |
| Hull, RD | 1 |
| Smith, MP | 2 |
| Steer, PJ | 2 |
| Cheer, SM | 1 |
| Foster, R | 1 |
| Savidge, G | 1 |
| Sharif, S | 1 |
| Hay, CR | 1 |
| Clayton-Smith, J | 1 |
| Yoneda, M | 1 |
| Brosnan, JF | 1 |
| Møller, AV | 1 |
| Jørgensen, SP | 1 |
| Chen, JW | 1 |
| Larnkjaer, A | 1 |
| Ledet, T | 1 |
| Flyvbjerg, A | 1 |
| Frystyk, J | 1 |
| Opara, E | 1 |
| Gile, J | 1 |
| Zaidi, J | 1 |
| Dendrinos, S | 1 |
| Kalogirou, I | 1 |
| Makrakis, E | 1 |
| Theodoridis, T | 1 |
| Mahmound, EA | 1 |
| Christopoulou-Cokkinou, V | 1 |
| Creatsas, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss ,Double Blinded Randomized Controlled Trial .[NCT05237843] | Phase 1 | 70 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
| Effects of Aspirin and Intrauterine Balloon on the Post-operative Uterine Endometrial Repair and Reproductive Prognosis in Patients With Severe Intrauterine Adhesion: a Prospective Cohort Study[NCT02744716] | 114 participants (Actual) | Interventional | 2011-05-31 | Completed | |||
| Low-molecular-weight Heparin to Prevent Recurrent VTE in Pregnancy: a Randomized Controlled Trial of Two Doses[NCT01828697] | Phase 4 | 1,110 participants (Actual) | Interventional | 2013-04-24 | Completed | ||
| Treatment of Intrauterine Growth Restriction With Low Molecular Heparin: Randomized Clinical Trial. Tratamiento Del Crecimiento Intrauterino Restringido Precoz Con Heparina de Bajo Peso Molecular: Ensayo clínico Aleatorizado.[NCT03324139] | Phase 3 | 50 participants (Anticipated) | Interventional | 2017-10-31 | Not yet recruiting | ||
| Assessing Women's Preferences for Postpartum Thromboprophylaxis: the PREFER-PostPartum[NCT05318547] | 52 participants (Anticipated) | Interventional | 2022-05-13 | Recruiting | |||
| Bemiparin Versus Enoxaparin as Thromboprophylaxis Following Vaginal and Abdominal Deliveries: A Prospective Clinical Trial[NCT01588171] | 7,020 participants (Actual) | Interventional | 2012-05-31 | Completed | |||
| Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery[NCT04305756] | 146 participants (Actual) | Interventional | 2020-06-12 | Completed | |||
| Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial[NCT02600260] | 7,212 participants (Actual) | Interventional | 2014-12-01 | Completed | |||
| Low Dose Aspirin and Low-molecular-weight Heparin in the Treatment of Pregnant Libyan Women With Recurrent Miscarriage[NCT01917799] | Phase 4 | 150 participants (Anticipated) | Interventional | 2009-01-31 | Recruiting | ||
| Essai thérapeutique randomisé Multicentrique en Double Insu, Comparant l'énoxaparine 40mg Versus Placebo, en Une Injection Sous-cutanée Quotidienne, Dans Les Fausses Couches spontanées récurrentes inexpliquées[NCT00740545] | Phase 3 | 258 participants (Actual) | Interventional | 2007-04-30 | Terminated (stopped due to Stopped for futility) | ||
| Comparing Anti-XA Levels in Post-Cesarean Patients With BMI >35 Undergoing Enoxaparin Thromboprophylaxis With Weight Based Dosing Twice Daily Versus Fixed Dose 40 Milligrams Daily[NCT02070237] | Phase 1 | 90 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| A Randomized Clinical Trial of Using Preconceptional Enoxaparin AND Low Dose Aspirin 81mg in Patient With Antiphospholipid Syndrome(APS)[NCT01661439] | 316 participants (Anticipated) | Observational | 2012-03-31 | Recruiting | |||
| Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome[NCT01068795] | 144 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
| Low Molecular Weight Heparin, Enoxaparin, to Prevent Adverse Maternal and Perinatal Outcomes in Women With Previous Severe Preeclampsia at Less Than 34 Weeks' Gestation. A Prospective Randomized Trial[NCT00986765] | Phase 3 | 257 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| anti10a Levels in Women Treated With LMWH in the Postpartum Period for Preventing Vein Thrombosis Events: A Comparison of Two Doses[NCT02856295] | Phase 4 | 136 participants (Actual) | Interventional | 2021-11-20 | Completed | ||
| [NCT00319176] | 15 participants (Anticipated) | Observational | 2004-04-30 | Completed | |||
| Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial[NCT01051778] | Phase 2 | 60 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Pharmacokinetics of Recombinant Antithrombin III in Neonates Undergoing Extracorporeal Membrane Oxygenation[NCT01913444] | Phase 4 | 0 participants (Actual) | Interventional | 2013-07-31 | Withdrawn (stopped due to Unable to enroll patients into study.) | ||
| An Investigation of Activated Factor XII (Fxlla) as a Prognostic Marker.[NCT00521976] | 871 participants (Actual) | Observational | 2002-11-30 | Completed | |||
| TIPPS - Thrombophilia in Pregnancy Prophylaxis Study: A Multicentre, Multinational, Randomized Control Trial of Prophylaxis Low Molecular Weight Heparin (LMWH) in High-risk Thrombophilic Women.[NCT00967382] | Phase 3 | 292 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| Postpartum Prophylaxis for PE Randomized Control Trial Pilot: A Pilot Study Assessing Feasibility of a Randomized, Open-label Trial of Low-Molecular-Weight-Heparin for Postpartum Prophylaxis in Women at Risk of Developing Venous Thromboembolism[NCT01274637] | Phase 3 | 62 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Phase III Study Analyzing the Effectiveness of Dalteparin Therapy as Intervention in Recurrent Pregnancy Loss[NCT00400387] | Phase 3 | 449 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Effect of Low-Molecular-Weight-Heparin (LMWH) on Pregnancy Outcome in Women With Multiple Failures of IVF-ET[NCT03701750] | Phase 4 | 240 participants (Anticipated) | Interventional | 2018-11-01 | Recruiting | ||
| Effects of UFH and LMWH on Osteoprotegerin and RANKL Plasma Levels in Hemodialysis Patients[NCT00669721] | 40 participants (Anticipated) | Interventional | 2008-03-31 | Recruiting | |||
| Weight-Adjusted Dosing of Tinzaparin in Pregnancy[NCT00851864] | Phase 4 | 13 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Our primary outcome will be to assess the Anti Xa level drawn 3.5-4 hours after the third dose of Lovenox (enoxaparin) to assess if this is in the prophylactic range. (NCT02070237)
Timeframe: 3.5-4 hours after the third dose of Lovenox (enoxaparin)
| Intervention | IU/mL (Mean) |
|---|---|
| Enoxaparin Once Daily | 0.14 |
| Enoxaparin Twice Daily | 0.30 |
We will assess if any of the subjects has an Anti Xa level that is in the supraprophylactic range (treatment range). (NCT02070237)
Timeframe: 3.5-4 hours after the third dose of Lovenox (enoxaparin)
| Intervention | participants (Number) |
|---|---|
| Enoxaparin Once Daily | 0 |
| Enoxaparin Twice Daily | 0 |
Live birth occurs when a fetus (> 24 weeks ) , exits the maternal body and subsequently shows signs of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord. (NCT01051778)
Timeframe: pregnancy > 24weeks gestation
| Intervention | Percentage of pregnancies (Number) |
|---|---|
| Enoxaparin 40 mg /Day Plus Low Dose Aspirin | 24 |
| Heparin Calcium 5,000 U Twice Daily Plus Low Dose Aspirin | 20 |
Recurrent Troponin-T (TnT) positive events; Symptoms of coronary ischemia associated with TnT >0.05 ng/mL with a pattern of gradual rise and fall in TnT (NCT00521976)
Timeframe: 24 months.
| Intervention | Participants (Number) |
|---|---|
| Group 1 | 155 |
(NCT00521976)
Timeframe: 24 months.
| Intervention | Participants. (Number) |
|---|---|
| Group 1 | 138 |
"If a subject dies between randomization and late postpartum follow up (Day 90 +/- 7 days) the death will be adjudicated as certain, highly probable, probable, or unlikely due to Pulmonary Embolism (PE) using the following criteria.~Certain: hypotension, hypoxia, cardiac arrest with no other explanation other than PE and autopsy or radiographic confirmation Highly probable: criteria for certain but another disease could have caused the death Probable: other cause suspected based on clinical evidence but 100% certainty not available Unlikely: all other cases." (NCT01274637)
Timeframe: From Randomization to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Molecular Weight Heparin | 0 |
| Control Group | 0 |
The average number of subjects that are recruited per site per month during a 4 month active recruitment phase at each site. (NCT01274637)
Timeframe: 4 months
| Intervention | participants per site per month (Number) |
|---|---|
| Low Molecular Weight Heparin | 0.9 |
| Control Group | 0.9 |
All subjects who develop thrombocytopenia (platelets less than 80 x 109/L and/or with >50% decrease from baseline) will be investigated for Heparin Induced Thrombocytopenia (HIT) by having ELISA and serotonin release assays to confirm or refute a diagnosis of HIT. HIT will be diagnosed with a positive PF4 (platelet factor 4) HIT ELISA assay. (NCT01274637)
Timeframe: From Randomization to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Molecular Weight Heparin | 0 |
| Control Group | 0 |
This includes symptomatic Deep Vein Thrombosis or Pulmonary Embolism. Suspected outcomes will be adjudicated by a blinded adjudication committee. (NCT01274637)
Timeframe: From Day 10 to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Molecular Weight Heparin | 0 |
| Control Group | 0 |
"Major bleeding meets at least one of the following: Fatal bleeding; Symptomatic bleeding in a critical area or organ (intracranial, intraspinal, retroperitoneal, etc.); Bleeding causing a fall in hemoglobin level of 20 g L-1 (1.24 mmol L-1) or more, or leading to transfusion of two or more units of whole blood or red cells .~Clinically Relevant Non-major Bleeding does not meet the criteria for major bleeding but meets at least one of the following: Hospitalization; Medical intervention; Unscheduled contact with a physician; Discomfort (pain, or impairment of activities of daily life)." (NCT01274637)
Timeframe: From Randomization to Day 90
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Molecular Weight Heparin | 3 |
| Control Group | 1 |
This includes symptomatic Deep Vein Thrombosis (DVT) or pulmonary embolism (PE) in the interval between randomization and the last dose of study drug (10 days +/- 3 days) OR asymptomatic proximal DVT detected by compression ultrasound of both legs done within 24hrs of the last dose of study drug (10 days (+/- 3 days) postpartum). Compressed and non-compressed images will be obtained from the calf trifurcation to the inguinal ligament. All suspected outcomes will be adjudicated by a blinded expert adjudication committee. (NCT01274637)
Timeframe: From randomization to Day 10
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Molecular Weight Heparin | 0 |
| Control Group | 0 |
35 reviews available for dalteparin and Pregnancy
| Article | Year |
|---|---|
Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia.
Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Enoxaparin; Female; Heparin, | 2014 |
Nadroparin carries a potentially high risk of inducing cutaneous delayed-type hypersensitivity responses.
Topics: Adult; Age Factors; Anticoagulants; Body Mass Index; Dermatitis, Allergic Contact; Drug Administrati | 2017 |
Use of the low-molecular-weight heparin nadroparin during pregnancy. A review.
Topics: Antiphospholipid Syndrome; Female; Fibrinolytic Agents; Heart Valve Prosthesis; Herpes Simplex; Huma | 2003 |
Plasma exchange in the management of high risk pregnant patients with primary antiphospholipid syndrome. A report of 9 cases and a review of the literature.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Female; Humans; Immunoglobulins, Intravenous; Nadr | 2007 |
[Successful prophylaxis in a pregnancy with thrombophilic states].
Topics: Acenocoumarol; Adult; Anticoagulants; Drug Therapy, Combination; Female; Gravidity; Humans; Nadropar | 1999 |
[Application of low-molecular-weight heparin during pregnancy and delivery in case of reproductive failure due to antiphospholipid syndrome].
Topics: Adult; Antiphospholipid Syndrome; Blood Coagulation; Cesarean Section; Female; Heparin, Low-Molecula | 2000 |
New frontiers with bemiparin: use in special populations.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Child; Female; Fibrinolytic Agents; Heparin, Low-Mol | 2010 |
Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Aspirin; Enoxaparin; Female; Hemorrhage; Humans; Pregnancy; Pregnancy Complications; | 2020 |
Factors effective in the prevention of Preeclampsia:A systematic review.
Topics: Arginine; Calcium; Drug Therapy, Combination; Enoxaparin; Female; Folic Acid; Heparin, Low-Molecular | 2020 |
Pregnancy outcome in a pregnant patient with idiopathic Pulmonary Arterial Hypertension: a case report and review of the literature.
Topics: Adult; Anticoagulants; Cesarean Section; Echocardiography; Enoxaparin; Familial Primary Pulmonary Hy | 2018 |
Risk Assessment and Treatment Guide for Obstetric Thromboprophylaxis: Comprehensive Review of Current Guidelines.
Topics: Anticoagulants; Enoxaparin; Female; Heparin; Humans; Postpartum Period; Practice Guidelines as Topic | 2019 |
Surgical Management of Placenta Accreta Spectrum.
Topics: Anticoagulants; Cesarean Section; Enoxaparin; Female; Gestational Age; Humans; Hysterectomy; Magneti | 2018 |
Enoxaparin (or plus aspirin) for the prevention of recurrent miscarriage: A meta-analysis of randomized controlled studies.
Topics: Abortion, Habitual; Anticoagulants; Aspirin; Enoxaparin; Female; Humans; Live Birth; Pre-Eclampsia; | 2019 |
The efficacy of enoxaparin for recurrent abortion: a meta-analysis of randomized controlled studies.
Topics: Abortion, Habitual; Enoxaparin; Female; Humans; Infant, Newborn; Live Birth; Pre-Eclampsia; Pregnanc | 2021 |
Pregnancy management in Behçet's disease treated with uninterrupted infliximab. Report of a case with fetal growth restriction and mini-review of the literature.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Anticoagulants; Behcet Syndrome; En | 2014 |
[Massive gestational vulvar edema. A case report and review of literature].
Topics: Albumins; Anti-Infective Agents; Anticoagulants; Cesarean Section; Edema; Enoxaparin; Exudates and T | 2014 |
LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia. A systematic review and meta-analysis.
Topics: Enoxaparin; Female; Fetal Growth Retardation; Heparin, Low-Molecular-Weight; Humans; Pre-Eclampsia; | 2016 |
[The antiphospholipid syndrome in the 21st century].
Topics: Adult; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Clinical Tri | 2009 |
Safety evaluation of enoxaparin in currently approved indications.
Topics: Adult; Animals; Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Myocardial Infarction; Posto | 2009 |
Thromboprophylaxis in medical patients: focus on France.
Topics: Acute Disease; Adult; Aged; Attitude of Health Personnel; Cardiovascular Diseases; Double-Blind Meth | 2002 |
Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.
Topics: Age Factors; Anticoagulants; Biological Availability; Clinical Trials as Topic; Enoxaparin; Female; | 2003 |
Thrombophilia and pregnancy complications.
Topics: Abortion, Habitual; Enoxaparin; Factor V; Female; Fetal Growth Retardation; Fibrinolytic Agents; Hum | 2004 |
The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients.
Topics: Anticoagulants; Drug Labeling; Enoxaparin; Evidence-Based Medicine; Female; Heart Valve Prosthesis; | 2005 |
Gestational thrombocythaemia associated with intrauterine death: case report and a review of the literature.
Topics: Anticoagulants; Enoxaparin; Female; Fetal Death; Humans; Placenta; Placenta Diseases; Pregnancy; Pre | 2006 |
Antiphospholipid syndrome in pregnancy.
Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin | 2008 |
Low molecular weight heparins and their use in obstetrics and gynecology.
Topics: Clinical Trials as Topic; Enoxaparin; Female; Fetus; Gynecology; Hemorrhage; Heparin, Low-Molecular- | 1994 |
[Treatment of venous thromboembolism].
Topics: Administration, Oral; Adult; Anticoagulants; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Hepar | 2000 |
Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism.
Topics: Adult; Anticoagulants; Catheterization, Central Venous; Child; Female; Hemorrhage; Heparin, Low-Mole | 2001 |
Reviparin sodium - a new low molecular weight heparin.
Topics: Absorption; Anticoagulants; Child; Drug Evaluation; Factor Xa Inhibitors; Female; Heparin, Low-Molec | 2002 |
Obstetric venous thromboembolism: a systematic review of dalteparin and pregnancy.
Topics: Adult; Anticoagulants; Dalteparin; Female; Humans; Postpartum Hemorrhage; Pregnancy; Pregnancy Compl | 2019 |
The use of low-molecular-weight heparin for the management of venous thromboembolism in pregnancy.
Topics: Abortion, Habitual; Analgesia, Epidural; Anticoagulants; Bone Density; Dalteparin; Female; Guideline | 2002 |
Low-molecular-weight heparins during pregnancy.
Topics: Anticoagulants; Dalteparin; Female; Heparin, Low-Molecular-Weight; Humans; Maternal-Fetal Exchange; | 2005 |
Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.
Topics: Blood Coagulation; Coronary Disease; Dalteparin; Drug Costs; Drug Interactions; Economics, Pharmaceu | 2000 |
Tinzaparin-a review of its molecular profile, pharmacology, special properties, and clinical uses.
Topics: Aged; Anticoagulants; COVID-19; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Pregnancy; T | 2022 |
Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.
Topics: Age Factors; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents | 2004 |
75 trials available for dalteparin and Pregnancy
| Article | Year |
|---|---|
Aspirin plus heparin or aspirin alone in women with recurrent miscarriage.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Contusions; Drug Therapy, Combination; Female; H | 2010 |
Aspirin plus heparin or aspirin alone in women with recurrent miscarriage.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Contusions; Drug Therapy, Combination; Female; H | 2010 |
Aspirin plus heparin or aspirin alone in women with recurrent miscarriage.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Contusions; Drug Therapy, Combination; Female; H | 2010 |
Aspirin plus heparin or aspirin alone in women with recurrent miscarriage.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Contusions; Drug Therapy, Combination; Female; H | 2010 |
Low molecular weight heparin treatment in pregnant women with a mechanical heart valve prosthesis.
Topics: Adult; Coumarins; Female; Heart Valve Diseases; Heart Valve Prosthesis; Humans; Hydrocephalus; Nadro | 2007 |
[Preparation for delivery in patients with missed labor considering low-dose heparin and prostaglandins].
Topics: Adult; Anticoagulants; Delivery, Obstetric; Dinoprostone; Female; Hemorrhage; Humans; Labor, Induced | 1996 |
Study protocol for a randomised controlled trial: treatment of early intrauterine growth restriction with low molecular weight heparin (TRACIP).
Topics: Female; Fetal Growth Retardation; Gestational Age; Heparin, Low-Molecular-Weight; Humans; Infant, Ne | 2018 |
Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Hematoma; Heparin, Low-Molecular-Weight | 2015 |
Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Hematoma; Heparin, Low-Molecular-Weight | 2015 |
Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Hematoma; Heparin, Low-Molecular-Weight | 2015 |
Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Hematoma; Heparin, Low-Molecular-Weight | 2015 |
Bemiparin versus low dose aspirin for management of recurrent early pregnancy losses due to antiphospholipd antibody syndrome.
Topics: Abortion, Habitual; Adult; Antiphospholipid Syndrome; Aspirin; Embryo Loss; Female; Heparin, Low-Mol | 2012 |
Weight-Based Compared With Fixed-Dose Enoxaparin Prophylaxis After Cesarean Delivery: A Randomized Controlled Trial.
Topics: Anticoagulants; Blood Coagulation; Cesarean Section; Enoxaparin; Female; Humans; Pregnancy; Venous T | 2022 |
Early Prophylactic Enoxaparin for the Prevention of Preeclampsia and Intrauterine Growth Restriction: A Randomized Trial.
Topics: Enoxaparin; Female; Fetal Growth Retardation; Heparin, Low-Molecular-Weight; Humans; Infant, Newborn | 2020 |
Therapeutic role of enoxaparin in intra-uterine growth restriction: A randomized clinical trial.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Fetal Growth Retardation; Gestational Age; Humans; Pregna | 2021 |
Placental Pathological Findings following Adjusting Enoxaparin Dosage in Thrombophilic Women: Secondary Analysis of a Randomized Controlled Trial.
Topics: Adolescent; Adult; Anticoagulants; Data Interpretation, Statistical; Drug Administration Schedule; E | 2019 |
Addition of prednisolone and heparin in patients with failed IVF/ICSI cycles: a preliminary report of a clinical trial.
Topics: Abortion, Spontaneous; Administration, Intravaginal; Administration, Oral; Adult; Anticoagulants; Ea | 2013 |
Low dose aspirin and low-molecular-weight heparin in the treatment of pregnant Libyan women with recurrent miscarriage.
Topics: Abortion, Habitual; Adult; Aspirin; Birth Weight; Embryo Implantation; Enoxaparin; Female; Fibrinoly | 2014 |
Enoxaparin for prevention of unexplained recurrent miscarriage: a multicenter randomized double-blind placebo-controlled trial.
Topics: Abortion, Habitual; Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Follow-Up Studie | 2015 |
ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia--study protocol for a randomized controlled trial.
Topics: Abortion, Habitual; Adolescent; Adult; Anticoagulants; Clinical Protocols; Drug Administration Sched | 2015 |
A randomized controlled trial of differing doses of postcesarean enoxaparin thromboprophylaxis in obese women.
Topics: Adult; Blood Coagulation; Body Mass Index; Chemoprevention; Dose-Response Relationship, Drug; Drug A | 2016 |
Randomized controlled study of pre-conception thromboprophylaxis among patients with recurrent spontaneous abortion related to antiphospholipid syndrome.
Topics: Abortion, Habitual; Adult; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Egypt; Eno | 2016 |
Adjusting enoxaparin dosage according to anti-FXa levels and pregnancy outcome in thrombophilic women. A randomised controlled trial.
Topics: Adult; Anticoagulants; Birth Weight; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Infant, Newbo | 2016 |
Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial.
Topics: Abruptio Placentae; Adult; Aspirin; Drug Therapy, Combination; Enoxaparin; Female; Humans; Pre-Eclam | 2016 |
The Prevalence of Thrombophilia in Women With Recurrent Fetal Loss and Outcome of Anticoagulation Therapy for the Prevention of Miscarriages.
Topics: Abortion, Habitual; Adolescent; Adult; Anticoagulants; Aspirin; Enoxaparin; Female; Humans; Middle A | 2018 |
Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: a prospective randomized placebo-controlled trial.
Topics: Adult; Anticoagulants; DNA; Embryo Implantation; Embryo Transfer; Enoxaparin; Factor V; Female; Fert | 2008 |
Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss.
Topics: Abortion, Habitual; Abortion, Spontaneous; Adult; Anticoagulants; Blood Coagulation Disorders; Dose- | 2009 |
SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Enoxaparin; Female; Humans; Infant, Newborn; Pla | 2010 |
A prospective trial showing the safety of adjusted-dose enoxaparin for thromboprophylaxis of pregnant women with mechanical prosthetic heart valves.
Topics: Adolescent; Adult; Anticoagulants; Enoxaparin; Female; Heart Valve Diseases; Heart Valve Prosthesis; | 2011 |
Influence of long-term thromboprophylaxis with low-molecular-weight heparin (enoxaparin) on changes of bone metabolism markers in pregnant women.
Topics: Adult; Alkaline Phosphatase; Anticoagulants; Bone and Bones; Enoxaparin; Female; Gestational Age; Hu | 2011 |
Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial.
Topics: Abruptio Placentae; Adult; Enoxaparin; Female; Humans; Pilot Projects; Pregnancy; Pregnancy Complica | 2010 |
High factor XI, recurrent pregnancy loss, enoxaparin.
Topics: Abortion, Habitual; Anticoagulants; Cohort Studies; Embryo Loss; Enoxaparin; Factor XI; Female; Homo | 2010 |
Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial.
Topics: Abortion, Habitual; Adolescent; Adult; Aspirin; Double-Blind Method; Drug Therapy, Combination; Earl | 2011 |
Efficacy and safety of two doses of low molecular weight heparin (enoxaparin) in pregnant women with a history of recurrent abortion secondary to antiphospholipid syndrome.
Topics: Abortion, Habitual; Adult; Anticoagulants; Antiphospholipid Syndrome; Enoxaparin; Female; Humans; In | 2010 |
Outcome of pregnancies in women with thrombophilic disorders.
Topics: Abortion, Habitual; Adult; Anticoagulants; Enoxaparin; Female; Fetal Death; Humans; Live Birth; Preg | 2010 |
The role of low-molecular-weight heparin in recurrent implantation failure: a prospective, quasi-randomized, controlled study.
Topics: Adult; Embryo Implantation; Embryo Transfer; Enoxaparin; Female; Humans; Infertility; Pregnancy; Pre | 2011 |
Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome.
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; | 2011 |
Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial.
Topics: Anticoagulants; Aspirin; Cohort Studies; Disease Progression; Enoxaparin; Female; Follow-Up Studies; | 2011 |
Anti-Xa activity with low-molecular-weight heparin, enoxaparin, during pregnancy in women with mechanical heart valves.
Topics: Adult; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Heart Valve Prosthesis; Heparin, Lo | 2002 |
Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia.
Topics: Abortion, Habitual; Adult; Birth Rate; Enoxaparin; Family Health; Female; Fibrinolytic Agents; Human | 2003 |
Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder.
Topics: Aspirin; Birth Weight; Enoxaparin; Female; Fetal Death; Folic Acid; Heparin, Low-Molecular-Weight; H | 2004 |
Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin.
Topics: Abortion, Habitual; Abortion, Spontaneous; Adult; Blood Coagulation Disorders; Case-Control Studies; | 2004 |
Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin.
Topics: Adult; Cesarean Section; Enoxaparin; Female; Fibrinolytic Agents; Humans; Osteoporosis; Patient Sele | 2004 |
Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study.
Topics: Abortion, Habitual; Dose-Response Relationship, Drug; Drug Hypersensitivity; Enoxaparin; Female; Hem | 2005 |
Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss.
Topics: Abortion, Habitual; Adult; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Product | 2005 |
A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages.
Topics: Abortion, Habitual; Abortion, Induced; Adult; Anticoagulants; Aspirin; Birth Rate; Birth Weight; Eno | 2006 |
Bone density changes in women who receive thromboprophylaxis in pregnancy.
Topics: Adult; Anticoagulants; Bone Density; Enoxaparin; Female; Heparin; Humans; Pregnancy; Prospective Stu | 2006 |
Treatment options and pregnancy outcome in women with idiopathic recurrent miscarriage: a randomized placebo-controlled study.
Topics: Abortion, Habitual; Adult; Anti-Inflammatory Agents; Aspirin; Drug Therapy, Combination; Enoxaparin; | 2008 |
Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Gestational Age; Humans; Metabolic Clearance Rate; Postpa | 2008 |
Use of a low-molecular weight heparin (enoxaparin) or of a phenformin-like substance (moroxydine chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity.
Topics: Abortion, Habitual; Adult; Biguanides; Double-Blind Method; Enoxaparin; Female; Fibrinolysis; Humans | 1995 |
Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy.
Topics: Adult; Analysis of Variance; Enoxaparin; Female; Fibrinolytic Agents; Humans; Injections, Subcutaneo | 1999 |
Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Topics: Adolescent; Adult; Anticoagulants; Antithrombin III; Cesarean Section; Dalteparin; Enoxaparin; Facto | 2001 |
Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Autoimmune D | 2001 |
Enoxaparin sodium improves pregnancy outcome in aspirin-resistant antiphospholipid/antiprotein antibody syndromes.
Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Drug Resistance; Enoxaparin; | 2002 |
Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial.
Topics: Adult; Dalteparin; Female; Fibrinolytic Agents; Hemorrhage; Humans; Pregnancy; Pregnancy Complicatio | 2014 |
Low-molecular-weight heparin to prevent postpartum venous thromboembolism. A pilot randomised placebo-controlled trial.
Topics: Adult; Anticoagulants; Dalteparin; Double-Blind Method; Drug Administration Schedule; Feasibility St | 2015 |
Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme.
Topics: Abortion, Habitual; Anticoagulants; Dalteparin; Female; Heparin, Low-Molecular-Weight; Humans; Injec | 2015 |
Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial.
Topics: Adult; Dalteparin; Female; Fetal Death; Humans; Infant, Low Birth Weight; Infant, Newborn; Pilot Pro | 2009 |
Use of heparin in women with early and late miscarriages with and without thrombophilia.
Topics: Abortion, Habitual; Adult; Age Factors; Aspirin; Biomarkers; Case-Control Studies; Dalteparin; Drug | 2009 |
Effect of dalteparin sodium administration on IVF outcome in non-thrombophilic young women: a pilot study.
Topics: Adult; Dalteparin; Embryo Implantation; Embryo Transfer; Female; Fertilization in Vitro; Humans; Ovu | 2011 |
Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event.
Topics: Adult; Cohort Studies; Dalteparin; Female; Fibrinolytic Agents; Humans; Middle Aged; Pregnancy; Preg | 2003 |
Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Dalteparin; Female; Heparin; Humans; Pilo | 2004 |
A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation.
Topics: Abortion, Spontaneous; Adult; Anticoagulants; Dalteparin; Dose-Response Relationship, Drug; Female; | 2004 |
Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women.
Topics: Adult; Anticoagulants; Birth Weight; Circadian Rhythm; Dalteparin; Diastole; Female; Fetal Growth Re | 2005 |
Changes in plasma coagulation markers with prophylactic treatment of low molecular weight heparin after cesarean section.
Topics: Adult; Biomarkers; Blood Coagulation; Cesarean Section; Dalteparin; Female; Fibrin Fibrinogen Degrad | 2005 |
The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial.
Topics: Adult; Anticoagulants; Antithrombin III; Biomarkers; Blood Coagulation; Dalteparin; Female; Heparin, | 2007 |
Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial.
Topics: Adult; Anticoagulants; Bone Density; Bone Diseases, Metabolic; Dalteparin; Female; Humans; Middle Ag | 2007 |
The rheological changes after cesarean section: The influence of low molecular weight or unfractionated heparin on the rheological properties of blood.
Topics: Adult; Biomarkers; Blood Coagulation; Blood Viscosity; Cesarean Section; Dalteparin; Female; Hemorhe | 2007 |
Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women.
Topics: Adult; Anticoagulants; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 2007 |
Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study.
Topics: Adult; Dalteparin; Drug Administration Schedule; Female; Humans; Longitudinal Studies; Pregnancy; Pr | 1998 |
A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy.
Topics: Adult; Anticoagulants; Antithrombin III; Area Under Curve; Circadian Rhythm; Cross-Over Studies; Dal | 1998 |
Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy.
Topics: Adult; Dalteparin; Demography; Female; Fractures, Bone; Hemorrhage; Heparin; Heparin, Low-Molecular- | 1999 |
Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin.
Topics: Adult; Anticoagulants; Body Mass Index; Body Weight; Dalteparin; Drug Monitoring; Female; Follow-Up | 2000 |
The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation.
Topics: Adult; Anticoagulants; Case-Control Studies; Dalteparin; Factor V; Female; Hemostasis; Hemostatics; | 2001 |
Increased thromboxane production in women with a history of venous thromboembolic event: effect of heparins.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Analysis of Variance; Anticoagulants; Body Mass Index; Case-Con | 2001 |
Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin.
Topics: Absorptiometry, Photon; Adult; Anticoagulants; Bone Density; Dalteparin; Factor Xa Inhibitors; Femal | 2002 |
Low-Molecular-Weight Heparin for the Treatment of Unexplained Recurrent Miscarriage With Negative Antiphospholipid Antibodies: A Randomized Controlled Trial.
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Female; Folic Acid; Heparin, Low-Molecular- | 2017 |
Thrombin generation post elective caesarean section: effect of low molecular weight heparin.
Topics: Adult; Anticoagulants; Cesarean Section; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; | 2012 |
Weight-adjusted dosing of tinzaparin in pregnancy.
Topics: Adult; Body Weight; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Heparin, Low-Mole | 2013 |
Tinzaparin sodium for thrombosis treatment and prevention during pregnancy.
Topics: Female; Fibrinolytic Agents; Gestational Age; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Preg | 2004 |
Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss.
Topics: Abortion, Habitual; Adult; Aspirin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Huma | 2007 |
275 other studies available for dalteparin and Pregnancy
| Article | Year |
|---|---|
Effect of low-molecular-weight heparins on anti-Xa peak levels and adverse reactions in Chinese patients with recurrent spontaneous abortion: a single-center, observational study.
Topics: Abortion, Habitual; Adult; Anticoagulants; Asian People; Blood Coagulation; China; Dalteparin; Drug | 2021 |
Localized and Generalized Skin Adverse Drug Reactions to Nadroparin Calcium Injection in 6 Cases of Pregnant Women.
Topics: Drug-Related Side Effects and Adverse Reactions; Female; Humans; Nadroparin; Pregnancy; Pregnant Wom | 2022 |
Low molecular weight heparin (nadroparin) improves placental permeability in rats with gestational diabetes mellitus via reduction of tight junction factors.
Topics: Animals; Diabetes, Gestational; Disease Models, Animal; Female; Glycation End Products, Advanced; Na | 2020 |
Thrombogenesis in Thrombophilic Pregnancy: Evaluation of Low-Molecular-Weight Heparin Prophylaxis.
Topics: Adult; Anticoagulants; Case-Control Studies; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-We | 2017 |
Efficacy and safety of nadroparin and unfractionated heparin for the treatment of venous thromboembolism during pregnancy and puerperium.
Topics: Anticoagulants; Female; Fibrinolytic Agents; Heparin; Humans; Nadroparin; Pregnancy; Pregnancy Compl | 2010 |
Antithrombotic therapy for recurrent miscarriage?
Topics: Abortion, Habitual; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Humans; Nadroparin; | 2010 |
[Position of Experts Panel of the Polish Gynecological Society in the application of low molecular weight heparin - nadroparin calcium (Fraxiparine) in obstetrics and gynecology].
Topics: Anticoagulants; Female; Fibrinolytic Agents; Gynecology; Humans; Nadroparin; National Health Program | 2011 |
Thrombophylaxis and bleeding complications after cesarean section.
Topics: Adult; Cesarean Section; Cohort Studies; Cross-Sectional Studies; Dalteparin; Drug Therapy, Combinat | 2012 |
[Successful pregnancy outcome in the woman with thrombophilia and multiple miscarriages].
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Cesarean Section; Factor V; Female; Heterozygote | 2003 |
Thrombosis of a prosthetic aortic valve during pregnancy despite therapeutic dosage of Nadroparin.
Topics: Adult; Aortic Valve; Female; Heart Valve Prosthesis; Heparin; Heparin, Low-Molecular-Weight; Humans; | 2004 |
Efficacy and safety of nadroparin in the treatment of pregnant women with antiphospholipid syndrome: a prospective cohort study.
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Female; Follow-Up St | 2005 |
Pregnancy and Takayasu's arteritis of the pulmonary artery.
Topics: Adult; Anticoagulants; Female; Humans; Methylprednisolone; Nadroparin; Pregnancy; Pregnancy Complica | 2005 |
Pharmacological correction of hemostasis-regulating function of the lungs in rats with uncomplicated pregnancy and experimental gestosis.
Topics: Animals; Anticoagulants; Birth Weight; Blood Coagulation; Blood Coagulation Disorders; Female; Fetal | 2005 |
Pharmacological correction of changes in the lung-placenta system under experimental conditions.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Fibrinogen; Hydrocortison | 2005 |
Pregnancy in a woman with a history of Budd-Chiari syndrome treated by porto-systemic shunt, protein C deficiency and bicornuate uterus.
Topics: Adult; Anticoagulants; Budd-Chiari Syndrome; Female; Humans; Labor, Induced; Nadroparin; Portasystem | 2006 |
Treatment of antiphospholipid syndrome in pregnancy with low doses of intravenous immunoglobulin.
Topics: Adult; Anti-Inflammatory Agents; Antiphospholipid Syndrome; Autoantibodies; Dexamethasone; Dose-Resp | 2007 |
Delayed hypersensitivity to low-molecular-weight heparin (LMWH) in pregnancy.
Topics: Adult; Anticoagulants; Cortisone; Drug Eruptions; Female; Fibrinolytic Agents; Follow-Up Studies; Fo | 2007 |
High-dose intravenous immunoglobulin treatment of a pregnant patient with an antiphospholipid syndrome: immunological changes associated with a successful outcome.
Topics: Adult; Antibodies, Anti-Idiotypic; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; | 1994 |
[The use of fraxiparin for the prevention and treatment of thromboembolism in patients with heparin-induced thrombocytopenia].
Topics: Adult; Disseminated Intravascular Coagulation; Drug Evaluation; Female; Heparin; Humans; Male; Middl | 1993 |
[Use of low molecular weight heparins].
Topics: Anesthesia, Epidural; Anesthesia, Obstetrical; Anticoagulants; Antithrombin III Deficiency; Cesarean | 1997 |
[Thromboembolism prophylaxis in pregnancy and labor].
Topics: Anticoagulants; Drug Administration Schedule; Female; Heart Valve Prosthesis; Hemostasis; Humans; Na | 1996 |
Is there a safe anticoagulation protocol for pregnant women with prosthetic valves?
Topics: Adult; Anticoagulants; Female; Fetal Death; Heart Valve Prosthesis; Heparin; Humans; Nadroparin; Obs | 1998 |
[Thrombophilia, anticoagulant therapy and pregnancy].
Topics: Adult; Anticoagulants; Female; Heparin, Low-Molecular-Weight; Humans; Maternal Mortality; Nadroparin | 1998 |
Low-molecular-weight heparin and thromboembolism in pregnancy.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Female; Hemorrhage; Heparin, Low-Molecular-Weight; | 1999 |
[Hip fracture during pregancy in a woman with transient osteporosis].
Topics: Accidental Falls; Adult; Anticoagulants; Bone Screws; Cesarean Section; Female; Fracture Fixation, I | 2010 |
Does low molecular weight heparin really protect against prosthetic valve thrombosis during pregnancy with strict anti-Xa monitoring?
Topics: Anticoagulants; Enoxaparin; Female; Heart Valve Diseases; Heart Valve Prosthesis; Heparin, Low-Molec | 2021 |
New generation oral anticoagulant apixaban enhances embryo implantation by increasing integrin β3 expression in rats: A pilot study.
Topics: Animals; Anticoagulants; Embryo Implantation; Enoxaparin; Female; Integrin beta3; Pilot Projects; Pr | 2022 |
Enoxaparin Increases D6 Receptor Expression and Restores Cytoskeleton Organization in Trophoblast Cells from Preeclampsia.
Topics: Cytoskeleton; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Pre-Eclampsia; Pregnancy; T | 2022 |
Prednisolone and enoxaparin (clexane) therapy ('the Bondi protocol') for repeated IVF failure.
Topics: Adult; Birth Rate; Enoxaparin; Female; Fertilization in Vitro; Humans; Live Birth; Prednisolone; Pre | 2022 |
Tumour necrosis factor inhibitor combined with intravenous immunoglobulin and heparin for treatment of recurrent spontaneous abortion: A two-centre, retrospective, cohort study.
Topics: Abortion, Habitual; Anticoagulants; Cohort Studies; Enoxaparin; Female; Heparin; Humans; Immunoglobu | 2022 |
Tumour necrosis factor inhibitor combined with intravenous immunoglobulin and heparin for treatment of recurrent spontaneous abortion: A two-centre, retrospective, cohort study.
Topics: Abortion, Habitual; Anticoagulants; Cohort Studies; Enoxaparin; Female; Heparin; Humans; Immunoglobu | 2022 |
Tumour necrosis factor inhibitor combined with intravenous immunoglobulin and heparin for treatment of recurrent spontaneous abortion: A two-centre, retrospective, cohort study.
Topics: Abortion, Habitual; Anticoagulants; Cohort Studies; Enoxaparin; Female; Heparin; Humans; Immunoglobu | 2022 |
Tumour necrosis factor inhibitor combined with intravenous immunoglobulin and heparin for treatment of recurrent spontaneous abortion: A two-centre, retrospective, cohort study.
Topics: Abortion, Habitual; Anticoagulants; Cohort Studies; Enoxaparin; Female; Heparin; Humans; Immunoglobu | 2022 |
Effects of anti-Xa activity monitoring on the outcome of high-risk pregnancies treated with a prophylactic dose of low-molecular-weight heparin.
Topics: Anticoagulants; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Infant, Newborn; Pregnanc | 2023 |
Delayed-type hypersensitivity reaction to enoxaparin in a pregnant woman.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Enoxaparin; Female; Humans; Hypersensitivity, Dela | 2019 |
Prospective evaluation of pregnancy outcome in an Italian woman with late-onset combined homocystinuria and methylmalonic aciduria.
Topics: Abortion, Spontaneous; Adult; Anticoagulants; Enoxaparin; Female; Fetal Growth Retardation; Homocyst | 2019 |
Factors associated with pregnancy outcomes in women with a history of cerebral sinus venous thrombosis.
Topics: Abortion, Spontaneous; Abruptio Placentae; Adult; Anticoagulants; Case-Control Studies; Enoxaparin; | 2020 |
Changes in serum D-dimer level and effect of enoxaparin sodium after a cesarean section: a retrospective study.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Fibrin Fibrinogen Degradation Products; | 2022 |
A prospective cohort study comparing achieved anti-factor Xa peak levels in pregnant and non-pregnant patients receiving therapeutic-dose low-molecular-weight heparin.
Topics: Adult; Anticoagulants; Biomarkers; Body Mass Index; Cohort Studies; Drug Monitoring; Enoxaparin; Fac | 2020 |
COVID-19 and Acute Pulmonary Embolism in Postpartum Patient.
Topics: Acute Disease; Adult; Anticoagulants; Betacoronavirus; Cesarean Section; Clinical Laboratory Techniq | 2020 |
A Pregnant Woman With Shortness of Breath.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Anticoagulants; Cesarean Section; Dyspnea; Echocardio | 2021 |
Giant intrahepatic venous malformation with localized intravascular coagulopathy. Follow-up and treatment during pregnancy.
Topics: Abortion, Habitual; Adult; Anticoagulants; Blood Coagulation Disorders; Cesarean Section; Enoxaparin | 2020 |
More on enoxaparin thromboprophylaxis in pregnancy: A review of 10 years' experience from King's College Hospital.
Topics: Anticoagulants; Enoxaparin; Female; Hospitals; Humans; Pregnancy; Universities; Venous Thromboemboli | 2021 |
NETosis Markers in Pregnancy: Effects Differ According to Histone Subtypes.
Topics: Adult; Apoptosis; Aspirin; Cell Line; Cell Movement; Enoxaparin; Extracellular Traps; Female; France | 2021 |
Letter to the Editor Regarding Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-analysis. Are All the Underlying Data True?
Topics: Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Venous Thromboembolism | 2021 |
Cerebral Venous Thrombosis and Hypercoagulability Associated With In Vitro Fertilization.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Fertilization in Vitro; Humans; Intracranial Thrombosis; | 2021 |
Successful pregnancy after Intralipid addition to sildenafil and enoxaparin in woman with history of recurrent pregnancy loss (RPL).
Topics: Abortion, Habitual; Adult; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Outcome; Sildenafil Citr | 2016 |
Enhancement of trophoblast differentiation and survival by low molecular weight heparin requires heparin-binding EGF-like growth factor.
Topics: Abortion, Induced; Antibodies, Blocking; Anticoagulants; Apoptosis; Cell Differentiation; Cell Line; | 2017 |
Doppler velocimetry in fetal rats exposed to enoxaparin and unfractionated heparin (UFH) during pregnancy.
Topics: Animals; Anticoagulants; Blood Flow Velocity; Echocardiography, Doppler, Pulsed; Enoxaparin; Female; | 2017 |
Is a therapeutic anticoagulation window needed for delivery when using prophylactic low molecular weight heparin during pregnancy? A retrospective monocentric study.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Delivery, Obstetric; Enoxaparin; Female; Heparin, | 2017 |
The Fetal Safety of Enoxaparin Use During Pregnancy: A Population-Based Retrospective Cohort Study.
Topics: Anticoagulants; Apgar Score; Cohort Studies; Congenital Abnormalities; Enoxaparin; Female; Fetal Dev | 2017 |
Outcomes of threatened abortions after anticoagulation treatment to prevent recurrent pregnancy loss.
Topics: Abortion, Habitual; Abortion, Threatened; Adult; Anticoagulants; Enoxaparin; Female; Humans; Live Bi | 2017 |
The association between anticoagulation therapy, maternal characteristics, and a failed cfDNA test due to a low fetal fraction.
Topics: Adult; Anticoagulants; Blood; Enoxaparin; Female; Humans; Maternal Serum Screening Tests; Middle Age | 2017 |
Pregnancy-related osteoporotic vertebral compression fractures in two patients treated with low-molecular-weight heparin during pregnancy: case reports.
Topics: Absorptiometry, Photon; Adult; Anticoagulants; Bone Density; Enoxaparin; Female; Fractures, Compress | 2018 |
Treatment of Prosthetic Valve Thrombosis with Bolus Dose Tenecteplase: An Experience from a Developing Country.
Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Aortic Valve; Developing Countries; Echocar | 2017 |
[Anticoagulation's problematic during pregnancy in carriers of mechanical heart prosthesis].
Topics: Abortion, Spontaneous; Acenocoumarol; Adult; Algeria; Anticoagulants; Enoxaparin; Female; Heart Valv | 2018 |
Improvement of maternal and fetal outcomes in women with sickle cell disease treated with early prophylactic erythrocytapheresis.
Topics: Abortion, Spontaneous; Adult; Anemia, Sickle Cell; Anticoagulants; Birth Weight; Cross-Sectional Stu | 2018 |
Risk assessment of venous thromboembolism and thromboprophylaxis in pregnant women hospitalized with cancer: Preliminary results from a risk score.
Topics: Adolescent; Adult; Anticoagulants; Enoxaparin; Female; Hospitalization; Humans; Longitudinal Studies | 2018 |
Women's views, adherence and experience with postnatal thromboprophylaxis.
Topics: Adult; Anticoagulants; Cesarean Section; Delivery, Obstetric; Enoxaparin; Female; Humans; Intermitte | 2019 |
Enoxaparin administration within 24 hours of caesarean section: a 6-year single-centre experience and patient outcomes.
Topics: Adult; Anticoagulants; Cesarean Section; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complicati | 2019 |
Safety and efficacy of adjusted-dose enoxaparin in pregnant patients with increased risk for venous thromboembolic disease.
Topics: Adult; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female; Humans; Postpartum Hemo | 2019 |
Enoxaparin (or plus aspirin) for the prevention of recurrent miscarriage: a meta-analysis of randomized controlled studies.
Topics: Abortion, Habitual; Anticoagulants; Aspirin; Enoxaparin; Female; Humans; Pregnancy; Prospective Stud | 2019 |
Effectiveness and safety of thromboprophylaxis with enoxaparin for prevention of pregnancy-associated venous thromboembolism.
Topics: Adult; Blood Coagulation; Dose-Response Relationship, Drug; Enoxaparin; Female; Fibrinolytic Agents; | 2019 |
Thromboprophylaxis in pregnant women: For whom and which LMWH dosage?
Topics: Anticoagulants; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnancy Comp | 2019 |
Cerebral venous sinus thrombosis during the first trimester after superovulation and intrauterine insemination with recombinant follicle-stimulating hormone: a case report.
Topics: Adult; Enoxaparin; Female; Follicle Stimulating Hormone; Heterozygote; Humans; Insemination; Methyle | 2013 |
[Parkes-Weber syndrome and pregnancy: anaesthetic implications].
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Anticoagulants; Arteriovenous Malformations; Emb | 2013 |
Pregnancy outcomes compared in women with mechanical heart valve replacements anticoagulated with warfarin and enoxaparin in pregnancy.
Topics: Anticoagulants; Cross-Over Studies; Enoxaparin; Female; Heart Valve Prosthesis; Heart Valves; Humans | 2012 |
Multidisciplinary approach in pregnancy-associated thrombotic thrombocytopenic purpura: a case report.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Anticoagulants; Cesarean Section; Combined Modality T | 2014 |
How I treat heterozygous hereditary antithrombin deficiency in pregnancy.
Topics: Adult; Antithrombin III; Antithrombin III Deficiency; Drug Administration Schedule; Enoxaparin; Fema | 2013 |
Population pharmacokinetics of enoxaparin during the antenatal period.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female; Humans; Pregnancy; Prenatal Ca | 2013 |
Peak plasma anti-Xa levels after first and third doses of enoxaparin in women receiving weight-based thromboprophylaxis following caesarean section: a prospective cohort study.
Topics: Adult; Anticoagulants; Body Mass Index; Cesarean Section; Cohort Studies; Enoxaparin; Factor Xa Inhi | 2013 |
Anticoagulation therapy: Enoxaparin dosing for VTE during pregnancy.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Prenatal Care | 2013 |
Comparative incidence of pregnancy outcomes in treated obstetric antiphospholipid syndrome: the NOH-APS observational study.
Topics: Abortion, Habitual; Abortion, Spontaneous; Adolescent; Adult; Antibodies, Anticardiolipin; Antibodie | 2014 |
[Takayasu's arteritis in pregnancy--a case report].
Topics: Antihypertensive Agents; Cesarean Section; Enoxaparin; Female; Humans; Infant, Newborn; Male; Pregna | 2014 |
Two successful pregnancies in a carrier of heterozygous factor V LEIDEN mutation with aplasia of the inferior vena cava and a history of proximal deep venous thrombosis.
Topics: Anticoagulants; Enoxaparin; Factor V; Female; Heterozygote; Humans; Iliac Vein; Live Birth; Mutation | 2014 |
Anticoagulant prescribing practices and anesthetic interventions among anticoagulated pregnant patients: a retrospective study.
Topics: Adult; Anesthesia, Epidural; Anesthesia, Obstetrical; Anticoagulants; Cohort Studies; Delivery, Obst | 2014 |
Restoration of ovarian function and natural fertility following the cryopreservation and autotransplantation of whole adult sheep ovaries.
Topics: Animals; Anti-Mullerian Hormone; Anticoagulants; Aspirin; Cryopreservation; Drug Therapy, Combinatio | 2014 |
Effects of enoxaparin and unfractionated heparin in prophylactic and therapeutic doses on the fertility of female Wistar rats.
Topics: Animals; Anticoagulants; Enoxaparin; Female; Fertility; Fetus; Hemorrhage; Heparin; Male; Placenta; | 2014 |
Oral anticoagulation with rivaroxaban during pregnancy: a case report.
Topics: Administration, Oral; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Drug Substitution; | 2014 |
Vitamin D reverses aPL-induced inflammation and LMWH-induced sFlt-1 release by human trophoblast.
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Antiphospholipid; Calcitriol; Cell Line; Cytokines; D | 2015 |
Postpartum osteoporosis and vertebral fractures in two patients treated with enoxaparin during pregnancy.
Topics: Absorptiometry, Photon; Adult; Anticoagulants; Bone Density; Enoxaparin; Female; Fractures, Compress | 2015 |
Prolonged anti-Xa activity due to enoxaparin at the end of pregnancy.
Topics: Adult; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Pregnancy; Time Factors | 2014 |
Does preoperative laboratory monitoring of antithrombotic therapy avoid adverse outcomes in patients undergoing surgery or regional anaesthesia?
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Pregnancy | 2014 |
Pregnancy in a patient with hepatic artery thrombosis after liver transplantation: a case report.
Topics: Activated Protein C Resistance; Adult; Anticoagulants; Collateral Circulation; Enoxaparin; Female; H | 2014 |
Changes in thrombin generation and D-dimer concentrations in women injecting enoxaparin during pregnancy and the puerperium.
Topics: Adolescent; Adult; Anticoagulants; Black People; Caribbean Region; Enoxaparin; Female; Fibrin Fibrin | 2014 |
Recurrent pregnancy loss: drop the heparin needles….
Topics: Abortion, Habitual; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complications | 2015 |
Enoxaparin dosing after cesarean delivery in morbidly obese women.
Topics: Adult; Anticoagulants; Body Mass Index; Body Weight; Cesarean Section; Drug Dosage Calculations; Dru | 2015 |
Pregnancy in a woman with pulmonary hypertension: favorable outcome with intravenous treprostinil.
Topics: Adult; Anticoagulants; Antihypertensive Agents; Cesarean Section; Enoxaparin; Epoprostenol; Female; | 2015 |
Evaluation of therapeutic enoxaparin in a pregnant population at a tertiary hospital.
Topics: Adolescent; Adult; Anticoagulants; Dose-Response Relationship, Drug; Drug Monitoring; Enoxaparin; Fe | 2016 |
Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy.
Topics: Adult; Antiphospholipid Syndrome; Endothelium; Enoxaparin; Female; Fibrinolytic Agents; Gestational | 2016 |
Repeated Thrombosis After Synthetic Cannabinoid Use.
Topics: Adult; Anticoagulants; Aspirin; Cannabinoids; Enoxaparin; Female; Humans; Infarction; Platelet Aggre | 2016 |
Birthweight in pregnant women with protein S deficiency treated with low-molecular-weight heparin: a retrospective cohort study.
Topics: Adult; Anticoagulants; Birth Weight; Case-Control Studies; Enoxaparin; Female; Fetal Growth Retardat | 2017 |
Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial.
Topics: Anticoagulants; Aspirin; Enoxaparin; Female; Humans; Placenta; Platelet Aggregation Inhibitors; Preg | 2017 |
Comparison of different dose regimens of enoxaparin in deep vein thrombosis therapy in pregnancy.
Topics: Adult; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female; Humans; Injections, Sub | 2008 |
Are anti-beta-glycoprotein-I antibodies markers for recurrent pregnancy loss in lupus anticoagulant/anticardiolipin seronegative women?
Topics: Abortion, Habitual; Adult; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants | 2008 |
Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis.
Topics: Adult; Anticoagulants; Antithrombin III; Body Mass Index; Body Weight; Dalteparin; Enoxaparin; Femal | 2008 |
Acute myocardial infarction in pregnancy.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Apgar Score; Aspirin; Cesarean Section; Coron | 2008 |
Spontaneous spinal epidural hematoma in pregnancy associated with using low molecular weight heparin.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Cesarean Section; Enoxaparin; Female; Hematoma, Ep | 2009 |
Intracranial subdural hematoma after spinal anesthesia in a parturient.
Topics: Adult; Anesthesia, Spinal; Anticoagulants; Cesarean Section; Enoxaparin; Female; Hematoma, Subdural, | 2009 |
Acenocoumarol and pregnancy outcome in a patient with mitral valve prosthesis: a case report.
Topics: Acenocoumarol; Adult; Anticoagulants; Enoxaparin; Female; Heart Valve Prosthesis; Humans; Male; Mitr | 2009 |
Systemic lupus erythematosus presenting with leukocytoclastic vasculitis and seizure during pregnancy.
Topics: Antibodies, Antinuclear; Anticoagulants; Enoxaparin; Female; Glucocorticoids; Humans; Intracranial T | 2009 |
Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy.
Topics: Abortion, Habitual; Abruptio Placentae; Adult; Afibrinogenemia; Enoxaparin; Female; Fibrinogen; Fibr | 2009 |
New observations in postpartum ovarian vein thrombosis: experience of single center.
Topics: Adult; Anticoagulants; Aspirin; Cesarean Section; Early Diagnosis; Enoxaparin; Female; Humans; Incid | 2010 |
Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin.
Topics: Anticoagulants; Delivery, Obstetric; Drug Administration Schedule; Drug Monitoring; Enoxaparin; Fema | 2009 |
A retrospective analysis of fondaparinux versus enoxaparin treatment in women with infertility or pregnancy loss.
Topics: Abortion, Spontaneous; Adult; Combined Modality Therapy; Enoxaparin; Female; Fondaparinux; Humans; I | 2009 |
Treatment of recurrent miscarriage and antiphospholipid syndrome with low-dose enoxaparin and aspirin.
Topics: Abortion, Habitual; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Dose-Response Relatio | 2009 |
Fluctuations in anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy.
Topics: Adult; Cross-Sectional Studies; Drug Administration Schedule; Drug Monitoring; Enoxaparin; Factor Xa | 2010 |
Obstetric patient on Lovenox therapy: evidence of heparin activity at 24 hours.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; Thro | 2010 |
First successful pregnancy after addition of enoxaparin to sildenafil and etanercept immunotherapy in woman with fifteen failed IVF cycles - case report.
Topics: Anticoagulants; Cytotoxicity, Immunologic; Drug Therapy, Combination; Endometriosis; Enoxaparin; Eta | 2010 |
Thrombocytosis associated with enoxaparin: A very rare cause in newborns.
Topics: Adolescent; Adult; Anticoagulants; Enoxaparin; Female; Humans; Infant, Newborn; Infant, Newborn, Dis | 2010 |
Etiological heterogeneity and clinical characteristics of metopic synostosis: Evidence from a tertiary craniofacial unit.
Topics: Adolescent; Anticoagulants; Child; Child, Preschool; Chromosome Aberrations; Craniosynostoses; Enoxa | 2010 |
[Parturient at full term with inferior vena cava thrombosis: anesthesia during surgical delivery].
Topics: Adult; Anesthesia, General; Anesthesia, Obstetrical; Anticoagulants; Cesarean Section; Emergencies; | 2010 |
Comparative immunological effect of anticoagulant and antioxidant therapy in the prevention of abortion in mice.
Topics: Abortion, Habitual; Abortion, Induced; Animals; Anticoagulants; Antioxidants; Enoxaparin; Female; Hu | 2011 |
Partial thrombus resolution with trofiban in a pregnant woman with mechanical prosthetic mitral valve thrombosis.
Topics: Adult; Echocardiography, Transesophageal; Enoxaparin; Female; Fibrinolytic Agents; Heart Valve Prost | 2011 |
Successful surgical management of massive pulmonary embolism during the second trimester in a parturient with heparin-induced thrombocytopenia.
Topics: Adult; Anticoagulants; Cardiopulmonary Bypass; Echocardiography, Transesophageal; Embolectomy; Enoxa | 2010 |
Pulmonary embolectomy in heparin-induced thrombocytopenia and thrombosis? Safety of heparin use.
Topics: Anticoagulants; Cardiopulmonary Bypass; Embolectomy; Enoxaparin; Female; Fondaparinux; Heart Arrest, | 2010 |
Limitation of proteinuria rise in diabetic pregnancy: possible benefits of enoxaparin.
Topics: Adult; Anticoagulants; Diabetes Mellitus, Type 1; Enoxaparin; Female; Humans; Pregnancy; Pregnancy i | 2010 |
A case of superior sagittal sinus thrombosis in pregnancy despite prophylactic antenatal heparin.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complications, Cardiovascula | 2010 |
Low molecular weight heparin treatment during subsequent pregnancies of women with inherited thrombophilia and previous severe pregnancy complications.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complications; Pregnancy Com | 2011 |
Recurrent miscarriages: caution regarding development of clinical trials using low molecular weight heparin and pregnancy.
Topics: Abortion, Habitual; Adult; Anticoagulants; Clinical Trials as Topic; Dose-Response Relationship, Dru | 2011 |
Fixed dosing regimes of enoxaparin for thromboprophylaxis do not reliably achieve target anti-Xa levels in women of normal weight during pregnancy.
Topics: Adult; Anticoagulants; Body Weight; Enoxaparin; Factor Xa; Female; Humans; Pregnancy; Pregnancy Comp | 2011 |
Birth defect rates in women using Adalimumab (Humira(®) ) to treat immunologic-based infertility in IVF patients.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Congenital Abnormali | 2011 |
Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: single-center experience.
Topics: Academic Medical Centers; Adult; Anticoagulants; Body Weight; Cohort Studies; Dalteparin; Dose-Respo | 2011 |
[Gastrointestinal stromal tumor in pregnancy and control. Case report].
Topics: Adult; Anticoagulants; Cesarean Section; Embolism, Amniotic Fluid; Emergencies; Enoxaparin; Female; | 2010 |
Maternal cardiovascular hemodynamics in a patient with mitral prosthetic heart valve evaluated with impedance cardiography and echocardiography.
Topics: Adult; Anticoagulants; Cardiography, Impedance; Diagnosis, Differential; Echocardiography; Enoxapari | 2011 |
Low-molecular-weight heparins induce decidual heparin-binding epidermal growth factor-like growth factor expression and promote survival of decidual cells undergoing apoptosis.
Topics: Anticoagulants; Apoptosis; Caspase 3; Caspase 8; Cell Survival; Decidua; Enoxaparin; Female; Gene Ex | 2012 |
Pulmonary arterial hypertension in the setting of pregnancy: a case series and standard treatment approach.
Topics: Adult; Algorithms; Anticoagulants; Antihypertensive Agents; Bosentan; Enoxaparin; Epoprostenol; Fema | 2012 |
Effects of low molecular weight heparin and heparin-binding epidermal growth factor on human trophoblast in first trimester.
Topics: Cell Differentiation; Cell Movement; Cell Proliferation; Cells, Cultured; Chorionic Gonadotropin; Cy | 2012 |
Leveraging physiological data from literature into a pharmacokinetic model to support informative clinical study design in pregnant women.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Body Water; Creatinine; Drug Monitoring; | 2012 |
Successful maternal-foetal outcome using nitric oxide and sildenafil in pulmonary hypertension with atrial septal defect and HIV infection.
Topics: Anti-HIV Agents; Anticoagulants; Enoxaparin; Female; Heart Septal Defects, Atrial; HIV Infections; H | 2012 |
Reference ranges for thromboelastography (TEG(®) ) and traditional coagulation tests in term parturients undergoing caesarean section under spinal anaesthesia*.
Topics: Adolescent; Adult; Anesthesia, Obstetrical; Anesthesia, Spinal; Anticoagulants; Blood Coagulation; B | 2012 |
Two vs. three or more primary recurrent pregnancy losses--are there any differences in epidemiologic characteristics and index pregnancy outcome?
Topics: Abortion, Habitual; Abortion, Spontaneous; Anticoagulants; Apgar Score; Cohort Studies; Enoxaparin; | 2012 |
Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study.
Topics: Adult; Aged; Anticoagulants; Canada; Catheterization; Coumarins; Disease Management; Drug Utilizatio | 2012 |
Emerging nonanticoagulant role of low molecular weight heparins on extravillous trophoblast functions and on heparin binding-epidermal growth factor and cystein-rich angiogenic inducer 61 expression.
Topics: Abortion, Habitual; Anticoagulants; Cell Differentiation; Cell Movement; Cells, Cultured; Cysteine-R | 2012 |
[Usefulness of a scoring system on perinatal outcomes in pregnant women with thrombophilia in the effectiveness of an enoxaparin-based intervention].
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complications, Hematologic; | 2012 |
Preventing adverse obstetric outcomes in women with genetic thrombophilia.
Topics: Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Pregnancy; Pregnancy Complication | 2002 |
Accidental spinal analgesia in the presence of a lumboperitoneal shunt in an obese parturient receiving enoxaparin therapy.
Topics: Adult; Anesthesia, Epidural; Anesthesia, Obstetrical; Anesthesia, Spinal; Anticoagulants; Cerebrospi | 2002 |
Fondaparinux sodium does not cross the placental barrier: study using the in-vitro human dually perfused cotyledon model.
Topics: Adult; Enoxaparin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Fondaparinux; Humans; In Vitro | 2002 |
ACOG Committee Opinion: safety of Lovenox in pregnancy.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complications, Hematologic; Safety | 2002 |
Treatment of acute pulmonary embolism during pregnancy with low molecular weight heparin: three case reports.
Topics: Acute Disease; Adult; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnanc | 2002 |
ACOG committee opinion. Safety of Lovenox in pregnancy. Number 276, October 2002. Committee on Obstetric Practice.
Topics: Anticoagulants; Drug Labeling; Enoxaparin; Female; Heart Valve Prosthesis; Humans; Pregnancy | 2002 |
Anticoagulation of pregnant women with mechanical heart valves.
Topics: Adult; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Heart Valve Prosthesis; Hep | 2003 |
Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen | 2003 |
Anticoagulation with prosthetic cardiac valves.
Topics: Anticoagulants; Enoxaparin; Female; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hum | 2003 |
Eczematous plaques related to unfractionated and low-molecular-weight heparin in pregnancy: cross-reaction with danaparoid sodium.
Topics: Adult; Aspirin; Chondroitin Sulfates; Dalteparin; Dermatan Sulfate; Drug Combinations; Drug Therapy, | 2003 |
Prosthetic heart valves and pregnancy.
Topics: Abnormalities, Drug-Induced; Anticoagulants; Enoxaparin; Female; Heart Valve Prosthesis; Humans; Pre | 2003 |
Prophylactic and therapeutic enoxaparin during pregnancy: indications, outcomes and monitoring.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complications, Cardiovascula | 2003 |
Life-threatening bleeding, pregnancy and lupus anticoagulant: success after steroid and anticoagulant therapy.
Topics: Adult; Antiphospholipid Syndrome; Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Glucocorticoids; | 2004 |
Post dural puncture headache in an anticoagulated patient.
Topics: Adult; Anticoagulants; Bed Rest; Blood Patch, Epidural; Dura Mater; Enoxaparin; Female; Headache; He | 2004 |
Epidural blood patch in a patient taking enoxaparin.
Topics: Adult; Blood Patch, Epidural; Enoxaparin; Factor V; Female; Headache; Hematoma, Epidural, Spinal; Hu | 2004 |
[Etiology and therapy of the internal jugular vein thrombosis].
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Cefuroxime; Cellulitis; Diagnosis, Differe | 2004 |
Low molecular weight heparin for repeated pregnancy loss: is it based on solid evidence?
Topics: Abortion, Habitual; Clinical Protocols; Clinical Trials as Topic; Enoxaparin; Female; Heparin, Low-M | 2005 |
The long and winding road ... towards LMWH for pregnancy loss.
Topics: Abortion, Habitual; Clinical Protocols; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; P | 2005 |
The safety of low molecular weight heparin therapy during labor.
Topics: Adult; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Hemoglobins; Hemorrhage; He | 2005 |
A protocol for the use of enoxaparin during pregnancy: results from 85 pregnancies including 13 multiple gestation pregnancies.
Topics: Adult; Aspirin; Clinical Protocols; Dose-Response Relationship, Drug; Drug Monitoring; Enoxaparin; F | 2005 |
Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the Live-Enox study.
Topics: Abortion, Habitual; Enoxaparin; Female; Humans; Infant, Newborn; Live Birth; Pregnancy; Pregnancy Co | 2005 |
Thrombophilia and pregnancy loss in first intended pregnancy.
Topics: Abortion, Habitual; Abortion, Spontaneous; Enoxaparin; Female; Gravidity; Humans; Pregnancy; Pregnan | 2005 |
Placental TFPI is decreased in gestational vascular complications and can be restored by maternal enoxaparin treatment.
Topics: Adult; Case-Control Studies; Enoxaparin; Female; Humans; Lipoproteins; Placenta; Placental Circulati | 2005 |
Budd-Chiari syndrome, systemic lupus erythematosus, and secondary antiphospholipid antibody syndrome in pregnancy.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Budd-Chiari Syndrome; Cholecystectom | 2005 |
Are low doses of enoxaparin with aspirin sufficient to guarantee good gestational outcome in women with heterozygote factor V Leiden mutation?
Topics: Abortion, Spontaneous; Adult; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Factor | 2007 |
Inherited thrombophilia: treatment during pregnancy.
Topics: Adult; Anticoagulants; Birth Weight; Cesarean Section; Delivery, Obstetric; Enoxaparin; Female; Feta | 2006 |
[Thromboembolisms endanger the internist patients, too: who needs heparin].
Topics: Age Factors; Aged; Anticoagulants; Dalteparin; Enoxaparin; Family Practice; Female; Fibrinolytic Age | 2006 |
The natural course of women with recurrent fetal loss.
Topics: Abortion, Habitual; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Enoxaparin; Female; Fibrinolyt | 2006 |
The effect of primary percutaneous coronary intervention as compared to tenecteplase on myeloperoxidase, pregnancy-associated plasma protein A, soluble fibrin and D-dimer in acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Enoxaparin; Female; Fibrin; Fibrin F | 2007 |
Investigation of the effects of heparin and low molecular weight heparin on E-cadherin and laminin expression in rat pregnancy by immunohistochemistry.
Topics: Abortion, Spontaneous; Animals; Anticoagulants; Cadherins; Disease Models, Animal; Enoxaparin; Femal | 2006 |
Massive subchorionic hematoma associated with enoxaparin.
Topics: Adult; Anticoagulants; Atrial Fibrillation; Cesarean Section; Chorion; Enoxaparin; Factor Xa Inhibit | 2006 |
Thrombelastography monitoring of resistance to enoxaparin anticoagulation in thrombophilic pregnancy patients.
Topics: Anticoagulants; Blood Coagulation; Case-Control Studies; Dose-Response Relationship, Drug; Drug Resi | 2007 |
Catastrophic antiphospholipid syndrome in the second trimester of pregnancy.
Topics: Abortion, Induced; Adult; Anti-Inflammatory Agents; Anticoagulants; Antineoplastic Agents, Hormonal; | 2006 |
[Analgesia for childbirth in a patient with factor V Leiden mutation].
Topics: Activated Protein C Resistance; Adult; Analgesia, Epidural; Analgesia, Obstetrical; Anticoagulants; | 2007 |
Congenital hypodysfibrinogenemia and abruptio placentae in a woman with history of cerebral thrombosis.
Topics: Abruptio Placentae; Adult; Anticoagulants; Enoxaparin; Female; Fibrinogens, Abnormal; Heparin; Human | 2007 |
Splenic rupture following elective caesarean delivery at term, complicated by low-molecular-weight heparin use.
Topics: Abdominal Pain; Adult; Anticoagulants; Antithrombin III Deficiency; Cesarean Section; Comorbidity; E | 2007 |
Comparison of the effects of unfractionated heparin and the low-molecular-weight heparins dalteparin and enoxaparin on spontaneous platelet aggregation and adenosine diphosphate activity in platelets during the third trimester of pregnancy.
Topics: Adenosine Diphosphate; Adult; Analysis of Variance; Anticoagulants; Apyrase; Blood Platelets; Daltep | 2007 |
Determination of anti-Xa levels in pregnant women treated with low molecular weight heparins for prevention of recurrent venous thromboembolism: a case report and review of the literature.
Topics: Adult; Disease Progression; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Female; Heparin, Low-Molecu | 2008 |
Timing of postpartum enoxaparin administration and severe postpartum hemorrhage.
Topics: Adult; Anticoagulants; Case-Control Studies; Cesarean Section; Drug Administration Schedule; Enoxapa | 2008 |
Feasibility of an easy-to-use risk score in the prevention of venous thromboembolism and placental vascular complications in pregnant women: a prospective cohort of 2736 women.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cohort Studies; Enoxaparin; Female | 2008 |
[Acute myocardial infarction in pregnancy of 39 week treated with fibrinolysis].
Topics: Adult; Cardiac Catheterization; Enoxaparin; Female; Fibrinolytic Agents; Humans; Infant, Newborn; My | 2008 |
Antithrombotic prophylaxis during pregnancy in women with deficiency of natural anticoagulants.
Topics: Abortion, Habitual; Adult; Anticoagulants; Cohort Studies; Enoxaparin; Female; Humans; Live Birth; P | 2008 |
[Stents, antiplatelet therapy, and surgery].
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cesarean Section; Enoxaparin; Female | 2008 |
Anesthetic management of a parturient with hyperhomocysteinemia.
Topics: Adult; Anesthesia, Spinal; Anesthetics, Inhalation; Anticoagulants; Blood Coagulation; Blood Coagula | 2008 |
Low molecular weight heparin for obstetric thromboprophylaxis.
Topics: Drug Costs; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnancy Complica | 1994 |
The use of low molecular weight heparin for thromboprophylaxis in pregnancy.
Topics: Adult; Dose-Response Relationship, Drug; Enoxaparin; Female; Gestational Age; Heparin; Humans; Pregn | 1994 |
Heparin-induced skin reaction due to two different preparations of low molecular weight heparin (LMWH)
Topics: Adult; Dalteparin; Drug Eruptions; Enoxaparin; Erythema; Female; Femoral Vein; Humans; Iliac Vein; P | 1993 |
Thrombocytopenia, antithrombin deficiency and extensive thromboembolism in pregnancy: treatment with low-molecular-weight heparin.
Topics: Adult; Antithrombin III; Antithrombin III Deficiency; Enoxaparin; Female; Fetal Death; Heparin; Huma | 1995 |
Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies.
Topics: Adult; Antiphospholipid Syndrome; Enoxaparin; Female; Fibrinolytic Agents; Humans; Labor, Obstetric; | 1996 |
[Breast-feeding is possible in case of maternal treatment with enoxaparin].
Topics: Anticoagulants; Breast Feeding; Enoxaparin; Female; Humans; Infant, Newborn; Postpartum Period; Preg | 1996 |
Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk.
Topics: Anticoagulants; Bone Density; Cohort Studies; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Pregn | 1997 |
Internal jugular vein thrombosis in patients with ovarian hyperstimulation syndrome.
Topics: Adult; Anticoagulants; Enoxaparin; Factor V; Female; Humans; Jugular Veins; Ovarian Hyperstimulation | 1998 |
Deep venous thrombosis in a preterm newborn of a mother with activated protein C resistance.
Topics: Adult; Blood Coagulation Disorders; Enoxaparin; Female; Humans; Infant, Newborn; Infant, Premature, | 1998 |
Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin.
Topics: Adult; Anticoagulants; Enoxaparin; Factor Xa; Female; Humans; Pregnancy; Pregnancy Complications, He | 1999 |
[Deep venous thrombosis during pregnancy: long-term treatment with low molecular weight heparin].
Topics: Adult; Dose-Response Relationship, Drug; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; | 1999 |
Low molecular weight heparin for thromboprophylaxis during caesarean section.
Topics: Adult; Antibodies; Blood Coagulation; Cesarean Section; Delivery, Obstetric; Enoxaparin; Factor Xa; | 1999 |
[Resistance to activated protein C and pregnancy: thromboprophylaxis with low molecular weight heparin].
Topics: Activated Protein C Resistance; Adult; Anticoagulants; Enoxaparin; Factor V; Female; Humans; Point M | 1999 |
Risk factors and management of patients with upper limb deep vein thrombosis.
Topics: Activated Protein C Resistance; Adult; Aged; Antithrombin III Deficiency; Drug Therapy, Combination; | 2000 |
Low-molecular-weight heparin for prosthetic heart valves: treatment failure.
Topics: Adult; Aged; Anticoagulants; Aortic Valve; Contraindications; Echocardiography; Enoxaparin; Female; | 2000 |
The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Factor V; | 2000 |
Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.
Topics: 3' Untranslated Regions; Abortion, Habitual; Activated Protein C Resistance; Adult; Anticoagulants; | 2000 |
Bleeding complications associated with low molecular weight heparin prophylaxis during pregnancy.
Topics: Anemia; Anticoagulants; Dalteparin; Delivery, Obstetric; Dextrans; Enoxaparin; Female; Hemorrhage; H | 2000 |
Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy.
Topics: Adolescent; Adult; Anticoagulants; Enoxaparin; Factor Xa; Female; Gestational Age; Humans; Pregnancy | 2000 |
A complication in anticoagulation using low-molecular weight heparin in a patient with a mechanical valve prosthesis. A case report.
Topics: Adult; Anticoagulants; Dilatation and Curettage; Enoxaparin; Female; Heart Valve Prosthesis; Heart V | 2000 |
Deep vein thrombosis during enoxaparin prophylactic treatment in a young pregnant woman homozygous for factor V Leiden and heterozygous for the G127-->a mutation in the thrombomodulin gene.
Topics: Adult; Anticoagulants; Enoxaparin; Factor V; Female; Humans; Point Mutation; Pregnancy; Pregnancy Co | 2000 |
Management of heparin allergy during pregnancy with danaparoid.
Topics: Adult; Cesarean Section; Chondroitin Sulfates; Dermatan Sulfate; Drug Combinations; Drug Hypersensit | 2001 |
Emergency redo mitral valve replacement in a 27-year-old pregnant female with a clotted prosthetic mitral valve, preoperative fetal demise and postoperative ventricular assist device: a case report.
Topics: Adult; Anticoagulants; Blood Coagulation; Cardiac Surgical Procedures; Cerebral Hemorrhage; Enoxapar | 2001 |
Cerebral venous thrombosis in young adults: 2 Case reports.
Topics: Adult; Cerebral Angiography; Diagnosis, Differential; Enoxaparin; Female; Fibrinolytic Agents; Hepar | 2001 |
Use of enoxaparin in a pregnant woman with a mechanical heart valve prosthesis.
Topics: Administration, Cutaneous; Adult; Anticoagulants; Aortic Valve; Contraindications; Enoxaparin; Femal | 2001 |
Intracranial bleed in a pregnant patient on oral anticoagulants for prosthetic heart valve.
Topics: Acenocoumarol; Adult; Anticoagulants; Aortic Valve; Enoxaparin; Female; Heart Valve Prosthesis; Huma | 2001 |
[Treatment with enoxaparin adapted to the fertility programs in women with recurrent abortion and thrombophilia].
Topics: Abortion, Habitual; Adult; Biomarkers; Embryo Loss; Enoxaparin; Female; Fibrinolytic Agents; Heparin | 2001 |
Enoxaparin treatment in women with mechanical heart valves during pregnancy.
Topics: Adult; Antibodies; Anticoagulants; Aspirin; Enoxaparin; Factor Xa; Female; Heart Valve Diseases; Hea | 2001 |
Cutaneous drug reaction case reports: from the world literature.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Aged; Amlodipine; Anti-Bacterial Agents; Anti-I | 2001 |
Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies.
Topics: Adult; Anticoagulants; Cerebral Hemorrhage; Enoxaparin; Female; Humans; Infant, Newborn; Intracrania | 2001 |
Absence of placental transfer of pentasaccharide (Fondaparinux, Arixtra) in the dually perfused human cotyledon in vitro.
Topics: Adult; Anticoagulants; Antipyrine; Enoxaparin; Female; Fetal Blood; Fondaparinux; Humans; In Vitro T | 2002 |
Pharmacokinetic profile of a low-molecular weight heparin (reviparin) in pregnant patients. A prospective cohort study.
Topics: Abortion, Habitual; Anticoagulants; Body Weight; Cohort Studies; Factor Xa Inhibitors; Female; Hepar | 2000 |
Comparison of doses of heparin for venous thromboembolism and bleeding in pregnant women.
Topics: Anticoagulants; Dalteparin; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Postpartum Hemor | 2022 |
Prophylactic Dose of Dalteparin in Pregnant Women With History of Venous Thromboembolisms and/or Thrombophilia: Real-World Data.
Topics: Anticoagulants; Dalteparin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pr | 2023 |
The antithrombin binding regions of heparin mediate fetal growth and reduced placental damage in the RUPP model of preeclampsia†.
Topics: Animals; Anticoagulants; Dalteparin; Female; Fetal Development; Gene Expression Regulation; Heparin; | 2020 |
Recurrent Massive Perivillous Fibrin Deposition and Chronic Intervillositis Treated With Heparin and Intravenous Immunoglobulin: A Case Report.
Topics: Abortion, Habitual; Abortion, Spontaneous; Adult; Anticoagulants; Aspirin; Chorionic Villi; Daltepar | 2017 |
Branch retinal artery occlusion as a clinical manifestation of hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome) in pregnancy.
Topics: Adult; Dalteparin; Echocardiography; Embolization, Therapeutic; Female; Fibrinolytic Agents; Humans; | 2018 |
Effects of glycol-split low molecular weight heparin on placental, endothelial, and anti-inflammatory pathways relevant to preeclampsia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Cell Adhesion; Complement Activation; Dalte | 2018 |
A case report of pulmonary arterial hypertension in pregnancy and complications of anticoagulation therapy.
Topics: Adult; Anticoagulants; Antihypertensive Agents; Cardiovascular Agents; Dalteparin; Epoprostenol; Fem | 2018 |
Hypoxia and the anticoagulants dalteparin and acetylsalicylic acid affect human placental amino acid transport.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Transport System A; Amino Acid Transport System L; | 2014 |
Recurrent cerebral ischaemia in a pregnant woman with patent foramen ovale II° and thrombophilia.
Topics: Adult; Anticoagulants; Brain Ischemia; Dalteparin; Female; Foramen Ovale, Patent; Humans; Injections | 2014 |
TIPPing practice away from anticoagulation in pregnancy.
Topics: Dalteparin; Female; Fibrinolytic Agents; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; | 2014 |
Dalteparin for pregnant women with thrombophilia.
Topics: Dalteparin; Female; Fibrinolytic Agents; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; | 2015 |
Dalteparin for pregnant women with thrombophilia.
Topics: Dalteparin; Female; Fibrinolytic Agents; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; | 2015 |
Dalteparin for pregnant women with thrombophilia.
Topics: Dalteparin; Female; Fibrinolytic Agents; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; | 2015 |
Dalteparin for pregnant women with thrombophilia - authors' reply.
Topics: Dalteparin; Female; Fibrinolytic Agents; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; | 2015 |
Effects of Sildenafil Citrate and Heparin Treatments on Placental Cell Morphology in a Murine Model of Pregnancy Loss.
Topics: Abortion, Habitual; Animals; Anticoagulants; Dalteparin; Disease Models, Animal; Female; Lipopolysac | 2016 |
The effect of dalteparin on thromboelastography in pregnancy: an in vitro study.
Topics: Adolescent; Adult; Anticoagulants; Dalteparin; Female; Humans; In Vitro Techniques; Middle Aged; Pil | 2016 |
[Pregnancy and childbirth in a patient with a spinal cord lesion].
Topics: Adult; Dalteparin; Delivery, Obstetric; Female; Humans; Infant, Newborn; Labor, Obstetric; Male; Pre | 2008 |
A prospective analysis of heparin-platelet factor 4 antibodies in pregnant women treated with the low-molecular-weight heparin, dalteparin.
Topics: Adult; Antibody Specificity; Antigens, Human Platelet; Autoantibodies; Autoantigens; Dalteparin; Dos | 2008 |
Transvaginal color Doppler for the visualization of pelvic vein thrombosis during pregnancy.
Topics: Adult; Anticoagulants; Dalteparin; Female; Humans; Iliac Vein; Pregnancy; Pregnancy Complications; T | 2009 |
Low molecular weight heparin stimulates myometrial contractility and cervical remodeling in vitro.
Topics: Adult; Anticoagulants; Cell Culture Techniques; Cervical Ripening; Cervix Uteri; Dalteparin; Female; | 2009 |
Does low molecular weight heparin shorten term labor?
Topics: Adolescent; Adult; Anesthesia, Epidural; Anesthesia, Obstetrical; Anticoagulants; Apgar Score; Dalte | 2010 |
Venous thromboembolism in pregnancy: prophylaxis and treatment with low molecular weight heparin.
Topics: Adult; Anticoagulants; Cesarean Section; Dalteparin; Female; Fetal Growth Retardation; Fibrinolytic | 2010 |
The effect of low molecular weight heparin (dalteparin) on duration and initiation of labour.
Topics: Adult; Anticoagulants; Case-Control Studies; Chi-Square Distribution; Dalteparin; Female; Gestationa | 2010 |
[Treating severe acute anemia due to vaginal bleeding in the Jehovah's Witness: a report of 2 cases].
Topics: Adult; Anemia; Anti-Anxiety Agents; Anticoagulants; Cervix Uteri; Combined Modality Therapy; Contrac | 2009 |
Management of severe mitral stenosis during pregnancy.
Topics: Adult; Anticoagulants; Catheterization; Dalteparin; Drug Therapy, Combination; Echocardiography, Dop | 2011 |
Heparin promotes soluble vascular enothelial growth factor receptor expression in human placental villi: a rebuttal.
Topics: Chorionic Villi; Dalteparin; Endothelium, Vascular; Female; Heparin, Low-Molecular-Weight; Humans; P | 2012 |
Triplet pregnancy in a Jehovah's witness: recombinant human erythropoietin and iron supplementation for minimising the risks of excessive blood loss.
Topics: Adult; Anticoagulants; Bandages; Blood Loss, Surgical; Cesarean Section; Christianity; Dalteparin; E | 2002 |
Treatment of deep venous thrombosis with low-molecular-weight heparin during pregnancy.
Topics: Adult; Dalteparin; Drug Evaluation; Female; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Huma | 2002 |
Thromboprophylaxis with low molecular weight heparin in thrombophilia-complicated pregnancy.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Dalteparin; Female; Humans; Pregnancy; Pregnancy C | 2002 |
Longitudinal evaluation of markers of endothelial cell dysfunction and hemostasis in treated antiphospholipid syndrome and in healthy pregnancy.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Biomarkers; Dalteparin; Endothelium, Vascular; F | 2003 |
Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy.
Topics: Acute Disease; Adult; Anticoagulants; Dalteparin; Factor Xa; Female; Humans; Norway; Pregnancy; Preg | 2003 |
A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy.
Topics: Abortion, Habitual; Analysis of Variance; Anticoagulants; Area Under Curve; Dalteparin; Dose-Respons | 2003 |
Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia.
Topics: Abruptio Placentae; Adult; Anticoagulants; Aspirin; Dalteparin; Drug Therapy, Combination; Female; F | 2007 |
The problem of risk assessment and prophylaxis of venous thromboembolism in pregnancy.
Topics: Anticoagulants; Dalteparin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; | 2007 |
[Successful therapy of heparin-associated thrombocytopenia with a low sulfated heparinoid].
Topics: Adult; Anticoagulants; Cesarean Section; Chondroitin Sulfates; Cross Reactions; Dalteparin; Dermatan | 1995 |
Bone density studies in pregnant women receiving heparin.
Topics: Anticoagulants; Antiphospholipid Syndrome; Bone Density; Case-Control Studies; Dalteparin; Female; H | 1996 |
Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies.
Topics: Adult; Anticoagulants; Dalteparin; Female; Humans; Injections, Subcutaneous; Pregnancy; Pregnancy Co | 1997 |
Thromboembolism treated with low molecular weight heparin in a pregnancy complicated by major placenta praevia: a case report.
Topics: Adult; Cesarean Section; Dalteparin; Female; Humans; Male; Molecular Weight; Placenta Previa; Pregna | 1997 |
[Does the pork/cat syndrome constitute a predisposition to heparin allergy?].
Topics: Adult; Allergens; Animals; Asthma; Blotting, Western; Cats; Cross Reactions; Dalteparin; Drug Erupti | 1997 |
Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin.
Topics: Adult; Anticoagulants; Antithrombins; Dalteparin; Female; Heparin; Hirudin Therapy; Humans; Lupus Er | 2000 |
Dalteparin sodium injection treatment in patients with immunologic recurrent pregnancy loss.
Topics: Abortion, Habitual; Adult; Anticoagulants; Dalteparin; Female; Humans; Injections, Subcutaneous; Pre | 2000 |
Drug eruption due to low molecular weight heparin.
Topics: Adult; Dalteparin; Drug Eruptions; Female; Fibrinolytic Agents; Humans; Injections, Subcutaneous; Pr | 2000 |
Accumulation of low molecular mass heparin during prophylactic treatment in pregnancy.
Topics: Adult; Anticoagulants; Dalteparin; Factor Xa Inhibitors; Female; Gestational Age; Heparin; Humans; P | 2001 |
A low-molecular-weight heparin preparation contraindicated during pregnancy.
Topics: Adult; Anticoagulants; Benzyl Alcohol; Contraindications; Dalteparin; Female; Humans; Infant; Pregna | 2001 |
Successful use of heparinoids in a pregnancy complicated by allergy to heparin.
Topics: Adult; Anticoagulants; Chondroitin Sulfates; Dalteparin; Dermatan Sulfate; Drug Combinations; Drug H | 2001 |
Cutaneous drug reaction case reports: from the world literature.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Bupropion; Celecoxib; Chlorquinaldol; Cytarabi | 2002 |
The assay of overall haemostasis potential used to monitor the low molecular mass (weight) heparin, dalteparin, treatment in pregnant women with previous thromboembolism.
Topics: Adult; Anticoagulants; Biomarkers; Blood Coagulation Tests; Dalteparin; Factor Xa Inhibitors; Female | 2002 |
[Prevention of thromboembolism with low molecular weight heparin (Dalteparin-Na) in risk pregnancy].
Topics: Adolescent; Adult; Antithrombin III; Dalteparin; Dose-Response Relationship, Drug; Female; Fibrin Fi | 2002 |
Tinzaparin thromboprophylaxis prescribing practice after caesarean delivery 2009-2014.
Topics: Cesarean Section; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; History, 21st Century; | 2018 |
Ovarian vein thrombosis after delivery.
Topics: Adult; Cesarean Section; Delivery, Obstetric; Diagnosis, Differential; Female; Follow-Up Studies; He | 2018 |
Tinzaparin safety and efficacy in pregnancy.
Topics: Abortion, Habitual; Adolescent; Adult; Drug Hypersensitivity; Female; Fibrinolytic Agents; Hemorrhag | 2014 |
Weight-adjusted LMWH prophylaxis provides more effective thrombin inhibition in morbidly obese pregnant women.
Topics: Adult; Body Weight; Cohort Studies; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Huma | 2014 |
Safety of therapeutic doses of tinzaparin during pregnancy.
Topics: Adult; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnancy Comp | 2015 |
Thromboelastography (TEG®) demonstrates that tinzaparin 4500 international units has no detectable anticoagulant activity after caesarean section.
Topics: Adult; Anticoagulants; Cesarean Section; Female; Heparin, Low-Molecular-Weight; Humans; Middle Aged; | 2017 |
Efficacy and safety of once daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy.
Topics: Adult; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fibri | 2008 |
Treatment of deep venous thrombosis in pregnant women.
Topics: Adult; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Gestatio | 2008 |
Tinzaparin failure in a pregnant patient with a mitral metal valve.
Topics: Adult; Female; Fibrinolytic Agents; Heart Valve Prosthesis; Heparin, Low-Molecular-Weight; Humans; P | 2008 |
[Thrombolytic therapy in pregnant woman with pulmonary embolism].
Topics: Adult; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnancy Comp | 2009 |
Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile.
Topics: Adolescent; Adult; Canada; Cohort Studies; Europe; Female; Fibrinolytic Agents; Heparin, Low-Molecul | 2011 |
Anticoagulation with Tinzaparin for women with mechanical valves in pregnancy: a retrospective case series.
Topics: Adult; Anticoagulants; Female; Fibrinolytic Agents; Heart Valve Prosthesis; Heparin, Low-Molecular-W | 2013 |
High-dose tinzaparin in pregnancy and the need for urgent delivery.
Topics: Adult; Anesthesia, Obstetrical; Anticoagulants; Female; Fibrinolytic Agents; Heparin, Low-Molecular- | 2002 |
Tinzaparin in the treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Fibri | 2003 |
Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study.
Topics: Adult; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Heparin, Low-Molecular-Weight | 2004 |
Aplasia cutis congenita and low molecular weight heparin.
Topics: Abnormalities, Drug-Induced; Adult; Ectodermal Dysplasia; Female; Fibrinolytic Agents; Heparin, Low- | 2005 |
The effect of LMWH (tinzaparin) on coagulation and fibrinolytic activation in pregnant women at risk of thrombosis.
Topics: Adult; Blood Coagulation; Factor Xa; Female; Fibrin Fibrinogen Degradation Products; Fibrinolysis; F | 2006 |
Glycosaminoglycans increase levels of free and bioactive IGF-I in vitro.
Topics: Adult; Anticoagulants; Dermatan Sulfate; Female; Fibrinolytic Agents; Glycosaminoglycans; Heparin; H | 2006 |
Inferior vena cava filter thrombo-prophylaxis in high-risk twin pregnancy.
Topics: Adult; Anticoagulants; Combined Modality Therapy; Female; Fibrinolytic Agents; Heparin; Heparin, Low | 2007 |